carvedilol and Myocardial Infarction studies

Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).

Research Excerpts

Excerpt	Relevance	Reference
"In patients after myocardial infarction, carvedilol added to background therapy improved insulin resistance and lipid profile."	9.12	After myocardial infarction carvedilol improves insulin resistance compared to metoprolol. ( Altuntas, Y; Basat, O; Oztekin, E; Seber, S; Ucak, S, 2006)
"We compared the pharmacokinetic (PK) profiles of repeated dosing with the currently available immediate-release (IR) carvedilol (given twice daily) and a newly developed controlled-release (CR) formulation (given once daily) in patients with left ventricular dysfunction (LVD)."	9.12	Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. ( Baidoo, CA; Greenberg, BH; Lukas, MA; Packer, M; Tenero, DM, 2006)
"We explored whether vascular protection by carvedilol could contribute to its superior effects in the treatment of heart failure (HF) compared with metoprolol tartrate in the COMET (Carvedilol Or Metoprolol European Trial) study."	9.12	Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007)
"In patients with depressed < or =35% ejection fraction after acute myocardial infarction treatment with low doses of metoprolol, bisoprolol and cardvediolol did not reduce mortality rate in 24-month observation."	9.12	[Effect of low doses of metoprolol, bisoprolol and carvedilol on mortality in patients with left ventricular dysfunction after acute myocardial infarction]. ( Chizyński, K; Goch, JH; Maciejewski, M; Ptaszyński, P; Ruta, J, 2006)
"Carvedilol, a beta1 and beta2 as well as an alpha1 adrenoreceptor antagonist with multiple hemodynamic, anti-ischemic and anti-oxidant properties, is widely accepted for the treatment of hypertension and congestive heart failure (CHF)."	9.12	The early anti-oxidant effect of carvedilol predicts the clinical course in congestive heart failure patients. ( Abinader, EG; Goldhammer, E; Lanir, A; Maor, I; Shnitzer, S, 2007)
"Carvedilol has previously been demonstrated to be beneficial in patients with acute myocardial infarction (AMI) and left ventricular (LV) dysfunction."	9.12	Randomized active-controlled study comparing effects of treatment with carvedilol versus metoprolol in patients with left ventricular dysfunction after acute myocardial infarction. ( Asanin, MR; Jelena, MM; Lasica, RM; Matic, MD; Mrdovic, IB; Ostojic, MC; Perunicic, JP; Savic, LZ; Vasiljevic, ZM, 2007)
" We determined the activities of copper-zinc superoxide dismutase (CuZnSOD), catalase, glutathione peroxidase and glutathione reductase in erythrocytes isolated from patients receiving different therapy (streptokinase alone or in combination with metoprolol or with carvedilol) for up to 168 hr after starting treatment for acute myocardial infarction."	9.12	Carvedilol increases copper-zinc superoxide dismutase activity in patients with acute myocardial infarction. ( Antonijević, NM; Blagojević, DP; Gojković-Bukarica, L; Jones, DR; Kastratović, DA; Lasica, RM; Marković, SZ; Matić, M; Mijalković, DN; Nikolić-Kokić, AL; Perunicić, JP; Spasić, MB; Stojiljkovic, MP; Vasiljević, ZM, 2007)
"The CAPRICORN trial has shown that carvedilol improved outcome in patients with left ventricular dysfunction after acute myocardial infarction treated with ACE inhibitors."	9.11	Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. ( Doughty, RN; Gamble, GD; López-Sendón, J; Sharpe, N; Walsh, HA; Whalley, GA, 2004)
" Before the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN)-a multicenter, multinational, double-blind, randomized, placebo-controlled trial that enrolled 1,959 patients who had an acute MI and a left ventricular ejection fraction of <==0."	9.11	Landmark study: the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN). ( Colucci, WS, 2004)
" To further explore the beneficial effects conferred by alpha-1-adrenoceptor blockade on ventricular repolarization dynamicity in the acute phase of myocardial infarction (AMI), we compared carvedilol with metoprolol in the setting of primary percutaneous coronary intervention (PCI)."	9.11	Carvedilol versus metoprolol in patients undergoing direct percutaneous coronary interventions for myocardial infarction: effects on QT dynamicity. ( Bode, F; Bonnemeier, H; Ortak, J; Richardt, G; Schmidt, J; Schunkert, H; Tölg, R; Wiegand, UK; Witt, M, 2005)
" To further explore the effects of additional alpha-1-adrenoceptor blockade on autonomic modulation in acute myocardial infarction (AMI), carvedilol was compared with metoprolol in the setting of primary percutaneous coronary interventions (PCI)."	9.11	Carvedilol versus metoprolol in the acute phase of myocardial infarction:. ( Bode, F; Bonnemeier, H; Ortak, J; Richardt, G; Schmidt, J; Schunkert, H; Tölg, R; Wiegand, UK; Witt, M, 2005)
"In a single-centre, randomized, open, endpoint-blinded, parallel group study, 232 patients with acute myocardial infarction were randomized to treatment with carvedilol or atenolol."	9.11	A comparison of the two beta-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction. a single-centre, randomized study of 232 patients. ( Abdelnoor, M; Jonsson, G; Kjeldsen, SE; Müller, C; Os, I; Westheim, A, 2005)
"In a randomized double-blind design, 3029 patients with chronic congestive heart failure requiring diuretic therapy and with left ventricular dysfunction were randomized to treatment with carvedilol (n = 1511) or metoprolol tartrate (n = 1518) and titrated to target doses of 25 mg of carvedilol twice daily or 50 mg of metoprolol tartrate twice daily."	9.11	Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET. ( Cleland, JG; Di Lenarda, A; Hanrath, P; Komajda, M; Lutiger, B; Metra, M; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Skene, A; Swedberg, K; Torp-Pedersen, C, 2005)
"To evaluate effects of carvedilol (Akridilol, AKRIKHIN, Russia) on central hemodynamics, microvascular bed, hemorheology, von Willebrand factor (VWF) activity, clinical efficacy of the drug and influence on exercise tolerance in patients with Q myocardial infarction (QMI) compared to therapy with atenolol."	9.11	[Carvedilol in combined therapy of patients with Q myocardial infarction]. ( Iakovleva, MS; Mironova, MA; Sadionchenko, VS; Shekhian, GG, 2005)
"The Carvedilol Acute Myocardial Infarction Study (CAMIS) investigates cardiac remodeling in patients (n = 250) randomized to carvedilol vs atenolol and treated for 12 months after acute myocardial infarction."	9.10	Lower plasma noradrenaline and blood viscosity on carvedilol vs atenolol in men with recent myocardial infarction. ( Eide, I; Fossum, E; Høieggen, A; Jonsson, G; Kjeldsen, SE; Os, I; Westheim, A, 2002)
"The aim of the study was to assess the effects of carvedilol, a vasodilating nonselective beta-blocker, on the indexes of left ventricular remodeling after acute myocardial infarction in those with left ventricular dysfunction."	9.09	Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction. ( Basu, S; Kinsey, C; Lahiri, A; Schaeffer, S; Senior, R, 1999)
"In patients treated long-term after an acute myocardial infarction complicated by left-ventricular systolic dysfunction, carvedilol reduced the frequency of all-cause and cardiovascular mortality, and recurrent, non-fatal myocardial infarctions."	9.09	Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. ( Dargie, HJ, 2001)
"Although carvedilol, a nonselective beta-blocker with alpha-adrenergic blocking and multiple ancillary activities, has been demonstrated to be superior to metoprolol in chronic heart failure, it remains unclear whether the superiority of carvedilol still exists in myocardial infarction (MI)."	8.95	Meta-Analysis Comparing Metoprolol and Carvedilol on Mortality Benefits in Patients With Acute Myocardial Infarction. ( Chen, Z; Gao, X; Ju, J; Li, J; Xiong, W; Xu, H; Zhang, H, 2017)
"The authors searched the English literature from 1984 to July 2010 via PubMed, EMBASE and SCOPUS using the following search terms: "cocaine-induced myocardial infarction AND treatment," "cocaine AND carvedilol," "beta blockers AND asthma," and "carvedilol AND asthma."	8.87	Carvedilol therapy after cocaine-induced myocardial infarction in patients with asthma. ( Mancell, J; Rogers, ML; Self, T; Soberman, JE, 2011)
"Carvedilol is a beta-adrenergic antagonist with vasodilatory properties (alpha1-antagonism), which has been extensively evaluated in the treatment of patients with heart failure."	8.84	Carvedilol: use in chronic heart failure. ( Doughty, RN; White, HD, 2007)
"The CAPRICORN (Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction) trial established that the beta-blocker carvedilol reduces the risk of death in patients with left ventricular dysfunction post myocardial infarction, whether or not the infarct is complicated by clinical heart failure."	8.82	New evidence from the CAPRICORN Trial: the role of carvedilol in high-risk, post-myocardial infarction patients. ( Sackner-Bernstein, JD, 2003)
" This study investigated the therapeutic benefit of adding rosuvastatin to low-dose carvedilol in protection against myocardial infarction (MI)."	8.02	Rosuvastatin and low-dose carvedilol combination protects against isoprenaline-induced myocardial infarction in rats: Role of PI3K/Akt/Nrf2/HO-1 signalling. ( Awad, AS; Baraka, SA; El-Demerdash, E; El-Naga, RN; Elsherbini, DA; Tolba, MF, 2021)
"Long term carvedilol therapy appears to be associated with a higher overall survival rate, improvement in ejection fraction and NYHA class in heart failure patients with preserved ejection fraction."	7.91	Effects of carvedilol therapy in patients with heart failure with preserved ejection fraction - Results from the Croatian heart failure (CRO-HF) registry. ( Branka, JZ; Davor, M; Domagoj, M; Duska, G; Jelena, M, 2019)
"This study was to assess effects of carvedilol on ventricular remodeling and expression of β3-adrenergic receptor (β3-AR) and Gi protein in a rat model of diabetes subjected to myocardial infarction (MI)."	7.83	Effects of carvedilol on ventricular remodeling and the expression of β3-adrenergic receptor in a diabetic rat model subjected myocardial infarction. ( Fu, L; Kang, X; Shen, J; Wang, F; Wang, Y; Yu, P; Zhang, R, 2016)
"The aim of this study was to investigate the effects of chronic treatment with carvedilol in blood pressure (BPV) and heart rate (HRV) variability of rats with myocardial infarction (MI)."	7.79	Carvedilol recovers normal blood pressure variability in rats with myocardial infarction. ( Andreão, RV; Baldo, MP; Cichoni, BS; Dantas, EM; Gonçalves, CP; Mill, JG; Pimentel, EB; Rodrigues, SL; Zaniqueli, Ddos A, 2013)
"This article reports the investigation of the effect of carvedilol (Car) on T-type calcium current (I(Ca,T)) of noninfarcted ventricular myocytes in rabbit models of healed myocardial infarction (HMI)."	7.78	[Effect of carvedilol on T-type calcium current in myocytes of non-infarcted area of the rabbit healed myocardial infarction]. ( Fu, YC; Gao, JL; Lan, YF; Li, Y; Lin, M; Liu, Y; Xu, B; Zhang, JC; Zhu, CX, 2012)
"The objective of this study was to investigate the effects of irbesartan, carvedilol, and irbesartan plus carvedilol on the expression of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) mRNA and protein in rat myocardium after myocardial infarction (MI)."	7.77	Combined effects of irbesartan and carvedilol on expression of tissue factor and tissue factor pathway inhibitor in rats after myocardial infarction. ( Du, Y; Ge, Z; Liu, W; Yu, J; Zhao, J, 2011)
"This 2-year comparative study of EchoCG data dynamics included 230 CHD patients after primary non-Q-wave myocardial infarction of whom 76 were treated with A CE inhibitor perindopril throughout the study period (group 1) and 72 with perindopril and carvedilol (non-selective alpha-1, beta-1,2 adrenergic receptor blocker) (group 2)."	7.77	[Effects of long-term therapy with angiotensin-converting enzyme inhibitor and carvedilol on the heart remodeling process after non-Q-wave myocardial infarction]. ( Bakaev, RG; Chudnovskaia, EA; Glazunov, AB; Kallaeva, AN; Kochetkov, BM; Moshkova, NK; Pekhtereva, DA; Strutynskiĭ, AV; Voronina, MA, 2011)
"We hypothesized that carvedilol, a nonselective β-blocker, can exert antiarrhythmogenic effects by inhibiting sympathetic nerve sprouting and electrical remodeling at peri-infarct zones after myocardial infarction (MI)."	7.76	Carvedilol ameliorates sympathetic nerve sprouting and electrical remodeling after myocardial infarction in rats. ( He, B; Hu, X; Huang, C; Jiang, H; Lu, Z; Tang, Q; Wen, H, 2010)
" Carvedilol, a nonselective beta-blocker, is widely used to prevent ventricular arrhythmias after myocardial infarction (MI)."	7.75	Carvedilol ameliorates the decreases in connexin 43 and ventricular fibrillation threshold in rats with myocardial infarction. ( Chen, J; He, B; Hu, X; Jiang, H; Lu, Z; Wen, H; Zhao, D, 2009)
"To study the effects of carvedilol combined with perindopril on Ca(2+) pump activity and the density of Ca(2+)-release channel ryanodine receptor (RyR2) in the myocardial sarcoplasmic reticulum (SR) in rats with chronic heart failure caused by myocardial infarction."	7.75	[Effect of carvedilol and perindopril on Ca(2+) pump activity and Ca(2+)-release channel density in myocardial sarcoplasmic reticulum in rats with chronic heart failure following myocardial infarction]. ( Cui, B; Geng, ZH; Li, LG; Liu, CY; Peng, YH; Yu, SY; Zhao, XH, 2009)
" In this study the effect of pretreatment of carvedilol on adrenaline-induced changes in the serum electrolytes (Mg2+, K+, Ca2+, Na+) was evaluated in rats."	7.75	Effect of carvedilol on adrenaline-induced changes in serum electrolytes in rat. ( Akhter, N; Nahar, N, 2009)
"The purpose of the present study was to study the influence of left ventricular myocardial infarction on gap junction protein connexin 40 in the atria, and to observe the intervention function of carvedilol as an adrenergic receptor blocker."	7.74	The influence of carvedilol on atrial connexin 40 after myocardial infarction. ( Bao, M; Cao, F; Huang, C; Jiang, H; Li, X; Tang, Y, 2008)
"To investigate the effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction (MI)."	7.74	[Effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction]. ( Chen, H; Guo, CY; Li, HW; Li, ZZ; Shen, LH; Sun, T; Tang, CS, 2008)
"Pretreatment with carvedilol preserves endothelial junctions and reduces myocardial no-reflow after acute myocardial infarction and reperfusion."	7.74	Carvedilol preserves endothelial junctions and reduces myocardial no-reflow after acute myocardial infarction and reperfusion. ( Cui, C; Gao, R; Yang, Y; you, S; Zhao, J, 2007)
" Treatment of myocardial infarction rabbits with carvedilol could restore it partially (5."	7.73	The beta-adrenergic blocker carvedilol restores L-type calcium current in a myocardial infarction model of rabbit. ( Cao, F; Huang, CX; Jiang, H; Li, X; Wang, T, 2005)
"To investigate the effects of carvedilol, irbesartan and their combination on myocardial collagen network remodeling after acute myocardial infarction (AMI) in rats."	7.73	[Experimental study of effect of carvedilol on myocardial collagen network remodeling after acute myocardial infarction in rats]. ( Bian, SY; Liu, HB; Wang, L; Yang, TS; Yang, X; Yi, J, 2005)
"To investigate the beneficial effects of carvedilol on cardiomyocyte apoptosis and related gene expression after acute myocardial infarction (AMI)."	7.73	[Beneficial effects of carvedilol on cardiomyocyte apoptosis and bcl-2/bax expression after acute myocardial infarction an experiment with rats]. ( Chen, JL; Chen, X; Chen, YF; Chen, ZJ; Gao, RL; Ruan, YM; Si, WX; Tian, Y; Wang, QZ; Yang, YJ; Zhang, HD; Zhou, YW, 2006)
"This study assessed the effects of combination therapy with simvastatin and carvedilol on clinical outcome in patients with left ventricular (LV) dysfunction after acute myocardial infarction (AMI)."	7.73	Effect of combination therapy with simvastatin and carvedilol in patients with left ventricular dysfunction complicated with acute myocardial infarction who underwent percutaneous coronary intervention. ( Ahn, Y; Cho, JG; Hong, SN; Hong, YJ; Hwang, SH; Jeong, MH; Kang, JC; Kim, JH; Kim, KH; Lee, SR; Park, HW; Park, JC; Yun, NS, 2006)
"It has been verified that losartan has beneficial effects on ventricular remodeling (VRM) after acute myocardial infarction (AMI), but the effects of carvedilol alone or in combination with losartan on this condition have not been defined."	7.72	Comparative effects of carvedilol and losartan alone and in combination for preventing left ventricular remodeling after acute myocardial infarction in rats. ( Chen, JL; Chen, ZJ; Gao, RL; Ruan, YM; Tang, YD; Wang, PH; Yang, YJ; Zhang, P; Zhou, YW, 2003)
"To compare the effects of carvedilol and metoprolol in preventing from left ventricular remodeling (LVRM) after acute myocardial infarction (AMI) in rats."	7.71	[Comparative effects of carvedilol and metoprolol in preventing from left ventricular remodeling after acute myocardial infarction in rats]. ( Chen, JL; Chen, ZJ; Gao, RL; Lu, SQ; Ruan, YM; Sun, RC; Tang, YD; Wang, PH; Yang, YJ; Zhang, P, 2001)
"To compare the effects of carvedilol, losartan and their combination in preventing from left ventricular remodeling (LVRM) after acute myocardial infarction(AMI) in rats."	7.71	[Comparative effects of carvedilol, losartan and their combination in preventing left ventricular remodeling after acute myocardial infarction in rats]. ( Chen, Z; Gao, R; Li, Y; Ruan, Y; Tang, Y; Yang, Y, 2001)
"Carvedilol (20 mg/kg, bid) or vehicle was given to rats surviving a myocardial infarction (MI) 24 h (n = 409)."	7.71	Long-term effects of carvedilol on left ventricular function, remodeling, and expression of cardiac cytokines after large myocardial infarction in the rat. ( Adam, A; Liu, P; Parker, TG; Rouleau, JL; Sia, YT; Tsoporis, JN, 2002)
"To compare the effects of cilazapril, carvedilol and their combination in preventing left ventricular remodelling (LVRM) after acute myocardial infarction (AMI) in rats."	7.71	Comparative effects of cilazapril, carvedilol and their combination in preventing from left ventricular remodelling after acute myocardial infarction in rats. ( Chen, J; Chen, Z; Gao, R; Li, Y; Ruan, Y; Tang, Y; Yang, Y; Zhou, Y, 2002)
" In the CAPITAL-RCT (Carvedilol Post-Intervention Long-Term Administration in Large-Scale Randomized Controlled Trial), patients with STEMI with successful percutaneous coronary intervention with an LVEF of ≥40% were randomly assigned to carvedilol or no β-blocker therapy."	7.30	Effects of Long-Term Carvedilol Therapy in Patients With ST-Segment Elevation Myocardial Infarction and Mildly Reduced Left Ventricular Ejection Fraction. ( Akao, M; Amano, M; Bingyuan, B; Furukawa, Y; Inada, T; Inuzuka, Y; Izumi, C; Kadota, K; Kaji, S; Kimura, T; Minamimoto, Y; Miyake, M; Morimoto, T; Nakagawa, Y; Ozasa, N; Suwa, S; Suzuki, T; Tamura, T; Watanabe, H, 2023)
"Carvedilol has a powerful antiarrhythmic effect after AMI, even in patients already treated with an ACE inhibitor."	6.71	Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. ( Colucci, W; Dargie, H; Ford, I; Køber, L; Lopez-Sendon, J; McMurray, J; Remme, W; Robertson, M; Sharpe, DN, 2005)
"Carvedilol was found to be safe, and it significantly reduced cardiac events compared with placebo (18 on carvedilol and 31 on placebo, P < ."	6.68	Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. ( Basu, S; Bruckner, T; Lahiri, A; Raval, U; Senior, R; van der Does, R, 1997)
" Beta-blocker dosage groups were >0% to12."	5.62	Comparison of Metoprolol Versus Carvedilol After Acute Myocardial Infarction. ( Fintel, DJ; Germano, JJ; Goldberger, JJ; Shani, J; Subacius, H; Zaatari, G, 2021)
"Carvedilol is a combined alpha(1)- and beta-adrenoceptor antagonist."	5.33	Carvedilol blockade of alpha1- and beta-adrenoceptor induced inotropic responses in rats with congestive heart failure. ( Bøkenes, J; Osnes, JB; Qvigstad, E; Schiander, I; Sejersted, OM; Sjaastad, I; Skomedal, T; Solberg, L, 2005)
"Treatment with carvedilol 1) reduced the pro-inflammatory cytokines and fibrogenic cytokine TGF-beta1 levels in myocardium and was associated with the amelioration of the elevated left ventricular diastolic pressure."	5.33	Effects of carvedilol on cardiac cytokines expression and remodeling in rat with acute myocardial infarction. ( Cheng, X; Ge, H; Guo, H; Li, B; Liao, YH; Wang, M, 2006)
"Carvedilol-treated animals exhibited a 78% reduction in infarct size compared to vehicle controls, such that the percentage of the left ventricle infarcted was reduced significantly from 16."	5.28	Carvedilol (Kredex) reduces infarct size in a canine model of acute myocardial infarction. ( Barone, FC; Feuerstein, GZ; Hamburger, SA; Ruffolo, RR, 1991)
"The datasets included in this pooling initiative were derived from 4 trials: CAPRICORN (Effect of Carvedilol on Outcome After Myocardial Infarction in Patients With Left Ventricular Dysfunction), OPTIMAAL (Optimal Trial in Myocardial Infarction With Angiotensin II Antagonist Losartan), VALIANT (Valsartan in Acute Myocardial Infarction Trial), and EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study); EPHESUS was used for external validation."	5.27	Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. ( Abdul-Rahim, AH; Dickstein, K; Ferreira, JP; Girerd, N; Gregson, J; Latar, I; McMurray, JJV; Pfeffer, MA; Pitt, B; Rossignol, P; Sharma, A; Zannad, F, 2018)
"In patients after myocardial infarction, carvedilol added to background therapy improved insulin resistance and lipid profile."	5.12	After myocardial infarction carvedilol improves insulin resistance compared to metoprolol. ( Altuntas, Y; Basat, O; Oztekin, E; Seber, S; Ucak, S, 2006)
"We compared the pharmacokinetic (PK) profiles of repeated dosing with the currently available immediate-release (IR) carvedilol (given twice daily) and a newly developed controlled-release (CR) formulation (given once daily) in patients with left ventricular dysfunction (LVD)."	5.12	Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. ( Baidoo, CA; Greenberg, BH; Lukas, MA; Packer, M; Tenero, DM, 2006)
"We explored whether vascular protection by carvedilol could contribute to its superior effects in the treatment of heart failure (HF) compared with metoprolol tartrate in the COMET (Carvedilol Or Metoprolol European Trial) study."	5.12	Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007)
"In patients with depressed < or =35% ejection fraction after acute myocardial infarction treatment with low doses of metoprolol, bisoprolol and cardvediolol did not reduce mortality rate in 24-month observation."	5.12	[Effect of low doses of metoprolol, bisoprolol and carvedilol on mortality in patients with left ventricular dysfunction after acute myocardial infarction]. ( Chizyński, K; Goch, JH; Maciejewski, M; Ptaszyński, P; Ruta, J, 2006)
"Carvedilol, a beta1 and beta2 as well as an alpha1 adrenoreceptor antagonist with multiple hemodynamic, anti-ischemic and anti-oxidant properties, is widely accepted for the treatment of hypertension and congestive heart failure (CHF)."	5.12	The early anti-oxidant effect of carvedilol predicts the clinical course in congestive heart failure patients. ( Abinader, EG; Goldhammer, E; Lanir, A; Maor, I; Shnitzer, S, 2007)
"Carvedilol has previously been demonstrated to be beneficial in patients with acute myocardial infarction (AMI) and left ventricular (LV) dysfunction."	5.12	Randomized active-controlled study comparing effects of treatment with carvedilol versus metoprolol in patients with left ventricular dysfunction after acute myocardial infarction. ( Asanin, MR; Jelena, MM; Lasica, RM; Matic, MD; Mrdovic, IB; Ostojic, MC; Perunicic, JP; Savic, LZ; Vasiljevic, ZM, 2007)
" We determined the activities of copper-zinc superoxide dismutase (CuZnSOD), catalase, glutathione peroxidase and glutathione reductase in erythrocytes isolated from patients receiving different therapy (streptokinase alone or in combination with metoprolol or with carvedilol) for up to 168 hr after starting treatment for acute myocardial infarction."	5.12	Carvedilol increases copper-zinc superoxide dismutase activity in patients with acute myocardial infarction. ( Antonijević, NM; Blagojević, DP; Gojković-Bukarica, L; Jones, DR; Kastratović, DA; Lasica, RM; Marković, SZ; Matić, M; Mijalković, DN; Nikolić-Kokić, AL; Perunicić, JP; Spasić, MB; Stojiljkovic, MP; Vasiljević, ZM, 2007)
"The purpose of the study was to evaluate the influence of metoprolol succinate and carvedilol on the physical ability (FA) of patients with chronic heart failure (CHF) of different etiologies."	5.12	[The effects of beta-adrenoblocker therapy on the physical working capacity of patients with chronic heart failure of various origin]. ( Andreev, DA; Kalashnikov, VIu; Poltavskaia, MG; Sarkisova, EA; Svet, AV; Syrkin, AL, 2007)
"The CAPRICORN trial has shown that carvedilol improved outcome in patients with left ventricular dysfunction after acute myocardial infarction treated with ACE inhibitors."	5.11	Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. ( Doughty, RN; Gamble, GD; López-Sendón, J; Sharpe, N; Walsh, HA; Whalley, GA, 2004)
" Before the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN)-a multicenter, multinational, double-blind, randomized, placebo-controlled trial that enrolled 1,959 patients who had an acute MI and a left ventricular ejection fraction of <==0."	5.11	Landmark study: the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN). ( Colucci, WS, 2004)
" To further explore the beneficial effects conferred by alpha-1-adrenoceptor blockade on ventricular repolarization dynamicity in the acute phase of myocardial infarction (AMI), we compared carvedilol with metoprolol in the setting of primary percutaneous coronary intervention (PCI)."	5.11	Carvedilol versus metoprolol in patients undergoing direct percutaneous coronary interventions for myocardial infarction: effects on QT dynamicity. ( Bode, F; Bonnemeier, H; Ortak, J; Richardt, G; Schmidt, J; Schunkert, H; Tölg, R; Wiegand, UK; Witt, M, 2005)
" To further explore the effects of additional alpha-1-adrenoceptor blockade on autonomic modulation in acute myocardial infarction (AMI), carvedilol was compared with metoprolol in the setting of primary percutaneous coronary interventions (PCI)."	5.11	Carvedilol versus metoprolol in the acute phase of myocardial infarction:. ( Bode, F; Bonnemeier, H; Ortak, J; Richardt, G; Schmidt, J; Schunkert, H; Tölg, R; Wiegand, UK; Witt, M, 2005)
"In a single-centre, randomized, open, endpoint-blinded, parallel group study, 232 patients with acute myocardial infarction were randomized to treatment with carvedilol or atenolol."	5.11	A comparison of the two beta-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction. a single-centre, randomized study of 232 patients. ( Abdelnoor, M; Jonsson, G; Kjeldsen, SE; Müller, C; Os, I; Westheim, A, 2005)
"In a randomized double-blind design, 3029 patients with chronic congestive heart failure requiring diuretic therapy and with left ventricular dysfunction were randomized to treatment with carvedilol (n = 1511) or metoprolol tartrate (n = 1518) and titrated to target doses of 25 mg of carvedilol twice daily or 50 mg of metoprolol tartrate twice daily."	5.11	Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET. ( Cleland, JG; Di Lenarda, A; Hanrath, P; Komajda, M; Lutiger, B; Metra, M; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Skene, A; Swedberg, K; Torp-Pedersen, C, 2005)
"To evaluate effects of carvedilol (Akridilol, AKRIKHIN, Russia) on central hemodynamics, microvascular bed, hemorheology, von Willebrand factor (VWF) activity, clinical efficacy of the drug and influence on exercise tolerance in patients with Q myocardial infarction (QMI) compared to therapy with atenolol."	5.11	[Carvedilol in combined therapy of patients with Q myocardial infarction]. ( Iakovleva, MS; Mironova, MA; Sadionchenko, VS; Shekhian, GG, 2005)
"The Carvedilol Acute Myocardial Infarction Study (CAMIS) investigates cardiac remodeling in patients (n = 250) randomized to carvedilol vs atenolol and treated for 12 months after acute myocardial infarction."	5.10	Lower plasma noradrenaline and blood viscosity on carvedilol vs atenolol in men with recent myocardial infarction. ( Eide, I; Fossum, E; Høieggen, A; Jonsson, G; Kjeldsen, SE; Os, I; Westheim, A, 2002)
"The aim of the study was to assess the effects of carvedilol, a vasodilating nonselective beta-blocker, on the indexes of left ventricular remodeling after acute myocardial infarction in those with left ventricular dysfunction."	5.09	Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction. ( Basu, S; Kinsey, C; Lahiri, A; Schaeffer, S; Senior, R, 1999)
"In patients treated long-term after an acute myocardial infarction complicated by left-ventricular systolic dysfunction, carvedilol reduced the frequency of all-cause and cardiovascular mortality, and recurrent, non-fatal myocardial infarctions."	5.09	Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. ( Dargie, HJ, 2001)
"Carvedilol is a non-selective beta-adrenoceptor antagonist with vasodilating properties which has been shown to be effective in the management both of hypertension and of stable angina pectoris."	5.08	Vasodilating beta-blockers in heart failure. ( Raftery, EB, 1995)
"To study the effects of the new vasodilating beta-blocking agent carvedilol on a variety of metabolic, hemodynamic, and ECG parameters of importance for the clinical outcome of acute myocardial infarction (AMI), we infused epinephrine (EPI) in healthy male volunteers on two separate occasions to serum concentrations of the same level reached in AMI."	5.07	Effects of carvedilol on the metabolic, hemodynamic, and electrocardiographic responses to increased plasma epinephrine in normal subjects. ( Eklund, B; Hansen, O; Johansson, BW; Nilsson-Ehle, P; Ohlsson, I; Palenmark, E; Pauler, AM; Svensson, K, 1994)
"Although carvedilol, a nonselective beta-blocker with alpha-adrenergic blocking and multiple ancillary activities, has been demonstrated to be superior to metoprolol in chronic heart failure, it remains unclear whether the superiority of carvedilol still exists in myocardial infarction (MI)."	4.95	Meta-Analysis Comparing Metoprolol and Carvedilol on Mortality Benefits in Patients With Acute Myocardial Infarction. ( Chen, Z; Gao, X; Ju, J; Li, J; Xiong, W; Xu, H; Zhang, H, 2017)
"Because carvedilol is a unique vasodilating β blocker (BB) exerting antioxidant activity and pleiotropic effects, it was theorized that it may confer more potent beneficial effects on cardiovascular mortality and morbidity in acute myocardial infarction (AMI) and heart failure (HF) settings."	4.89	Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol). ( DiNicolantonio, JJ; Fares, H; Lavie, CJ; Menezes, AR; O'Keefe, JH, 2013)
"The authors searched the English literature from 1984 to July 2010 via PubMed, EMBASE and SCOPUS using the following search terms: "cocaine-induced myocardial infarction AND treatment," "cocaine AND carvedilol," "beta blockers AND asthma," and "carvedilol AND asthma."	4.87	Carvedilol therapy after cocaine-induced myocardial infarction in patients with asthma. ( Mancell, J; Rogers, ML; Self, T; Soberman, JE, 2011)
"Carvedilol is a beta-adrenergic antagonist with vasodilatory properties (alpha1-antagonism), which has been extensively evaluated in the treatment of patients with heart failure."	4.84	Carvedilol: use in chronic heart failure. ( Doughty, RN; White, HD, 2007)
"The CAPRICORN (Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction) trial established that the beta-blocker carvedilol reduces the risk of death in patients with left ventricular dysfunction post myocardial infarction, whether or not the infarct is complicated by clinical heart failure."	4.82	New evidence from the CAPRICORN Trial: the role of carvedilol in high-risk, post-myocardial infarction patients. ( Sackner-Bernstein, JD, 2003)
" The remodeling effect of beta-blockade with carvedilol has been studied in patients with left ventricular dysfunction after myocardial infarction and in patients with chronic heart failure of ischemic etiology."	4.82	Cardiac remodeling in coronary artery disease. ( Sharpe, N, 2004)
"Carvedilol is a vasodilating, beta-adrenoceptor antagonist currently marketed for the treatment of mild to moderate hypertension."	4.79	Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. ( Feuerstein, GZ; Ruffolo, RR, 1995)
" This study investigated the therapeutic benefit of adding rosuvastatin to low-dose carvedilol in protection against myocardial infarction (MI)."	4.02	Rosuvastatin and low-dose carvedilol combination protects against isoprenaline-induced myocardial infarction in rats: Role of PI3K/Akt/Nrf2/HO-1 signalling. ( Awad, AS; Baraka, SA; El-Demerdash, E; El-Naga, RN; Elsherbini, DA; Tolba, MF, 2021)
"Long term carvedilol therapy appears to be associated with a higher overall survival rate, improvement in ejection fraction and NYHA class in heart failure patients with preserved ejection fraction."	3.91	Effects of carvedilol therapy in patients with heart failure with preserved ejection fraction - Results from the Croatian heart failure (CRO-HF) registry. ( Branka, JZ; Davor, M; Domagoj, M; Duska, G; Jelena, M, 2019)
"This study was to assess effects of carvedilol on ventricular remodeling and expression of β3-adrenergic receptor (β3-AR) and Gi protein in a rat model of diabetes subjected to myocardial infarction (MI)."	3.83	Effects of carvedilol on ventricular remodeling and the expression of β3-adrenergic receptor in a diabetic rat model subjected myocardial infarction. ( Fu, L; Kang, X; Shen, J; Wang, F; Wang, Y; Yu, P; Zhang, R, 2016)
"The aim of this study was to investigate the effects of chronic treatment with carvedilol in blood pressure (BPV) and heart rate (HRV) variability of rats with myocardial infarction (MI)."	3.79	Carvedilol recovers normal blood pressure variability in rats with myocardial infarction. ( Andreão, RV; Baldo, MP; Cichoni, BS; Dantas, EM; Gonçalves, CP; Mill, JG; Pimentel, EB; Rodrigues, SL; Zaniqueli, Ddos A, 2013)
"This article reports the investigation of the effect of carvedilol (Car) on T-type calcium current (I(Ca,T)) of noninfarcted ventricular myocytes in rabbit models of healed myocardial infarction (HMI)."	3.78	[Effect of carvedilol on T-type calcium current in myocytes of non-infarcted area of the rabbit healed myocardial infarction]. ( Fu, YC; Gao, JL; Lan, YF; Li, Y; Lin, M; Liu, Y; Xu, B; Zhang, JC; Zhu, CX, 2012)
"The objective of this study was to investigate the effects of irbesartan, carvedilol, and irbesartan plus carvedilol on the expression of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) mRNA and protein in rat myocardium after myocardial infarction (MI)."	3.77	Combined effects of irbesartan and carvedilol on expression of tissue factor and tissue factor pathway inhibitor in rats after myocardial infarction. ( Du, Y; Ge, Z; Liu, W; Yu, J; Zhao, J, 2011)
"This 2-year comparative study of EchoCG data dynamics included 230 CHD patients after primary non-Q-wave myocardial infarction of whom 76 were treated with A CE inhibitor perindopril throughout the study period (group 1) and 72 with perindopril and carvedilol (non-selective alpha-1, beta-1,2 adrenergic receptor blocker) (group 2)."	3.77	[Effects of long-term therapy with angiotensin-converting enzyme inhibitor and carvedilol on the heart remodeling process after non-Q-wave myocardial infarction]. ( Bakaev, RG; Chudnovskaia, EA; Glazunov, AB; Kallaeva, AN; Kochetkov, BM; Moshkova, NK; Pekhtereva, DA; Strutynskiĭ, AV; Voronina, MA, 2011)
"High-dose carvedilol alleviated LV remodelling and diastolic dysfunction following SVR accompanying with reduction in myocardial fibrosis."	3.76	Carvedilol may alleviate late cardiac remodelling following surgical ventricular restoration. ( Ikeda, T; Komeda, M; Marui, A; Muranaka, H; Nishina, T; Tsukashita, M; Wang, J; Yoshikawa, E, 2010)
"We hypothesized that carvedilol, a nonselective β-blocker, can exert antiarrhythmogenic effects by inhibiting sympathetic nerve sprouting and electrical remodeling at peri-infarct zones after myocardial infarction (MI)."	3.76	Carvedilol ameliorates sympathetic nerve sprouting and electrical remodeling after myocardial infarction in rats. ( He, B; Hu, X; Huang, C; Jiang, H; Lu, Z; Tang, Q; Wen, H, 2010)
" Carvedilol, a nonselective beta-blocker, is widely used to prevent ventricular arrhythmias after myocardial infarction (MI)."	3.75	Carvedilol ameliorates the decreases in connexin 43 and ventricular fibrillation threshold in rats with myocardial infarction. ( Chen, J; He, B; Hu, X; Jiang, H; Lu, Z; Wen, H; Zhao, D, 2009)
"To study the effects of carvedilol combined with perindopril on Ca(2+) pump activity and the density of Ca(2+)-release channel ryanodine receptor (RyR2) in the myocardial sarcoplasmic reticulum (SR) in rats with chronic heart failure caused by myocardial infarction."	3.75	[Effect of carvedilol and perindopril on Ca(2+) pump activity and Ca(2+)-release channel density in myocardial sarcoplasmic reticulum in rats with chronic heart failure following myocardial infarction]. ( Cui, B; Geng, ZH; Li, LG; Liu, CY; Peng, YH; Yu, SY; Zhao, XH, 2009)
" In this study the effect of pretreatment of carvedilol on adrenaline-induced changes in the serum electrolytes (Mg2+, K+, Ca2+, Na+) was evaluated in rats."	3.75	Effect of carvedilol on adrenaline-induced changes in serum electrolytes in rat. ( Akhter, N; Nahar, N, 2009)
"The purpose of the present study was to study the influence of left ventricular myocardial infarction on gap junction protein connexin 40 in the atria, and to observe the intervention function of carvedilol as an adrenergic receptor blocker."	3.74	The influence of carvedilol on atrial connexin 40 after myocardial infarction. ( Bao, M; Cao, F; Huang, C; Jiang, H; Li, X; Tang, Y, 2008)
"To investigate the effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction (MI)."	3.74	[Effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction]. ( Chen, H; Guo, CY; Li, HW; Li, ZZ; Shen, LH; Sun, T; Tang, CS, 2008)
"Pretreatment with carvedilol preserves endothelial junctions and reduces myocardial no-reflow after acute myocardial infarction and reperfusion."	3.74	Carvedilol preserves endothelial junctions and reduces myocardial no-reflow after acute myocardial infarction and reperfusion. ( Cui, C; Gao, R; Yang, Y; you, S; Zhao, J, 2007)
" Treatment of myocardial infarction rabbits with carvedilol could restore it partially (5."	3.73	The beta-adrenergic blocker carvedilol restores L-type calcium current in a myocardial infarction model of rabbit. ( Cao, F; Huang, CX; Jiang, H; Li, X; Wang, T, 2005)
"To investigate the effects of carvedilol, irbesartan and their combination on myocardial collagen network remodeling after acute myocardial infarction (AMI) in rats."	3.73	[Experimental study of effect of carvedilol on myocardial collagen network remodeling after acute myocardial infarction in rats]. ( Bian, SY; Liu, HB; Wang, L; Yang, TS; Yang, X; Yi, J, 2005)
"We investigated the change of LV remodeling and function in a rat model of heart failure due to myocardial infarction (MI) with or without carvedilol (30 mg/kg/d) or metoprolol (60 mg/kg/d) treatment for 6 weeks (n = 9 in the MI plus carvedilol group, and n = 8 in every other group)."	3.73	Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats. ( Hu, SJ; Hu, Y; Sun, YL; Wang, LH; Zhou, JY, 2005)
"To investigate the beneficial effects of carvedilol on cardiomyocyte apoptosis and related gene expression after acute myocardial infarction (AMI)."	3.73	[Beneficial effects of carvedilol on cardiomyocyte apoptosis and bcl-2/bax expression after acute myocardial infarction an experiment with rats]. ( Chen, JL; Chen, X; Chen, YF; Chen, ZJ; Gao, RL; Ruan, YM; Si, WX; Tian, Y; Wang, QZ; Yang, YJ; Zhang, HD; Zhou, YW, 2006)
"This study assessed the effects of combination therapy with simvastatin and carvedilol on clinical outcome in patients with left ventricular (LV) dysfunction after acute myocardial infarction (AMI)."	3.73	Effect of combination therapy with simvastatin and carvedilol in patients with left ventricular dysfunction complicated with acute myocardial infarction who underwent percutaneous coronary intervention. ( Ahn, Y; Cho, JG; Hong, SN; Hong, YJ; Hwang, SH; Jeong, MH; Kang, JC; Kim, JH; Kim, KH; Lee, SR; Park, HW; Park, JC; Yun, NS, 2006)
"It has been verified that losartan has beneficial effects on ventricular remodeling (VRM) after acute myocardial infarction (AMI), but the effects of carvedilol alone or in combination with losartan on this condition have not been defined."	3.72	Comparative effects of carvedilol and losartan alone and in combination for preventing left ventricular remodeling after acute myocardial infarction in rats. ( Chen, JL; Chen, ZJ; Gao, RL; Ruan, YM; Tang, YD; Wang, PH; Yang, YJ; Zhang, P; Zhou, YW, 2003)
"The dose-related beneficial effects of carvedilol on survival in heart failure have been verified, however, the effects on left ventricular remodeling (LVRM) after acute myocardial infarction (AMI) have not been defined."	3.72	Comparison of metoprolol with low, middle and high doses of carvedilol in prevention of postinfarction left ventricular remodeling in rats. ( Chen, J; Chen, Z; Gao, R; Ruan, Y; Tang, Y; Wang, Y; Yang, Y, 2003)
"Baroreflex sensitivity was assessed in 287 patients with history of myocardial infarction and left ventricular ejection fraction < or =40% by phenylephrine test and was found to be depressed (4."	3.72	[Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction]. ( Bozhko, AA; Kanopskiĭ, SG; Staritskiĭ, AG, 2004)
" For all these reasons, the CAPRICORN trial of carvedilol in post-MI left ventricular dysfunction was an important and eagerly awaited trial, which could show that carvedilol treatment post-MI on top of the so-called modern post-MI therapy reduces mortality."	3.71	[Beta blockers in post-infarction state]. ( Schultheiss, HP; Tschöpe, C, 2002)
"To compare the effects of carvedilol and metoprolol in preventing from left ventricular remodeling (LVRM) after acute myocardial infarction (AMI) in rats."	3.71	[Comparative effects of carvedilol and metoprolol in preventing from left ventricular remodeling after acute myocardial infarction in rats]. ( Chen, JL; Chen, ZJ; Gao, RL; Lu, SQ; Ruan, YM; Sun, RC; Tang, YD; Wang, PH; Yang, YJ; Zhang, P, 2001)
"To compare the effects of carvedilol, losartan and their combination in preventing from left ventricular remodeling (LVRM) after acute myocardial infarction(AMI) in rats."	3.71	[Comparative effects of carvedilol, losartan and their combination in preventing left ventricular remodeling after acute myocardial infarction in rats]. ( Chen, Z; Gao, R; Li, Y; Ruan, Y; Tang, Y; Yang, Y, 2001)
"To compare the effects of carvedilol in large, middle, or small dose in preventing left ventricular remodeling (LVRM) after acute myocardial infarction (AMI) in rats."	3.71	[Comparative effects of carvediol in large, middle, and small dose in preventing left ventricular remodeling after acute myocardial infarction in rats]. ( Tang, Y; Yang, Y; Zhang, P, 2001)
"Carvedilol (20 mg/kg, bid) or vehicle was given to rats surviving a myocardial infarction (MI) 24 h (n = 409)."	3.71	Long-term effects of carvedilol on left ventricular function, remodeling, and expression of cardiac cytokines after large myocardial infarction in the rat. ( Adam, A; Liu, P; Parker, TG; Rouleau, JL; Sia, YT; Tsoporis, JN, 2002)
"The CAPRICORN and COPERNICUS studies have confirmed the significance of betablocker treatment with carvedilol for indications which this medication did not yet possess: post-infarction with left ventricular dysfunction with or without clinical signs, and stable severe cardiac insufficiency."	3.71	[CAPRICORN and COPERINUS studies]. ( Juillière, Y, 2002)
"To compare the effects of cilazapril, carvedilol and their combination in preventing left ventricular remodelling (LVRM) after acute myocardial infarction (AMI) in rats."	3.71	Comparative effects of cilazapril, carvedilol and their combination in preventing from left ventricular remodelling after acute myocardial infarction in rats. ( Chen, J; Chen, Z; Gao, R; Li, Y; Ruan, Y; Tang, Y; Yang, Y; Zhou, Y, 2002)
"Carvedilol, a selective alpha1 and non-selective beta-adrenoceptor antagonist and antioxidant, has been shown to provide significant cardiac protection in animal models of myocardial ischemia."	3.70	Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model. ( Arch, JR; Cheng, HY; Feuerstein, G; Hieble, JP; Liu, GL; Ma, XL; Ruffolo, RR; Yue, TL, 1998)
"We sought to compare the effects of two different beta-blockers, carvedilol and metoprolol, to an angiotensin-converting enzyme (ACE) inhibitor (captopril) on myocardial collagen deposition during healing and ventricular remodeling after myocardial infarction (MI)."	3.70	Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction. ( Chow, LT; Sanderson, JE; Wei, S, 2000)
"Four different models of acute myocardial infarction in were examined in three animal species, and the effects of carvedilol were compared to those of propranolol."	3.68	Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity. ( Cheng, HY; Feuerstein, GZ; Ruffolo, RR; Yue, TL, 1993)
" The comparative ability of carvedilol and propranolol to reduce infarct size in experimental models of acute myocardial infarction in the rat, pig and dog has been investigated utilizing a variety of experimental techniques."	3.68	Cardioprotective potential of carvedilol. ( Bril, A; Feuerstein, GZ; Ruffolo, RR, 1993)
"The aim was to evaluate in a minipig model of acute myocardial infarction the cardioprotection provided by the beta adrenoceptor blocking and vasodilating activities present in carvedilol; comparison was made to the pure beta adrenoceptor antagonist, propranolol."	3.68	Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranolol. ( Bril, A; DiMartino, MJ; Feuerstein, GZ; Linee, P; Poyser, RH; Ruffolo, RR; Slivjak, M; Smith, EF, 1992)
" In the CAPITAL-RCT (Carvedilol Post-Intervention Long-Term Administration in Large-Scale Randomized Controlled Trial), patients with STEMI with successful percutaneous coronary intervention with an LVEF of ≥40% were randomly assigned to carvedilol or no β-blocker therapy."	3.30	Effects of Long-Term Carvedilol Therapy in Patients With ST-Segment Elevation Myocardial Infarction and Mildly Reduced Left Ventricular Ejection Fraction. ( Akao, M; Amano, M; Bingyuan, B; Furukawa, Y; Inada, T; Inuzuka, Y; Izumi, C; Kadota, K; Kaji, S; Kimura, T; Minamimoto, Y; Miyake, M; Morimoto, T; Nakagawa, Y; Ozasa, N; Suwa, S; Suzuki, T; Tamura, T; Watanabe, H, 2023)
"Carvedilol is a direct inhibitor of vascular smooth muscle cell migration and proliferation through inhibition of mitogen-activated protein kinase activity and regulation of cell cycle progression."	2.71	Comparison between a sustained administration of carvedilol versus atenolol to reduce restenosis after coronary stenting. ( Cha, KS; Kim, DI; Kim, DS; Kim, HJ; Kim, JS; Kim, JW; Kim, MH, 2004)
"Carvedilol has a powerful antiarrhythmic effect after AMI, even in patients already treated with an ACE inhibitor."	2.71	Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. ( Colucci, W; Dargie, H; Ford, I; Køber, L; Lopez-Sendon, J; McMurray, J; Remme, W; Robertson, M; Sharpe, DN, 2005)
"Carvedilol was found to be safe, and it significantly reduced cardiac events compared with placebo (18 on carvedilol and 31 on placebo, P < ."	2.68	Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. ( Basu, S; Bruckner, T; Lahiri, A; Raval, U; Senior, R; van der Does, R, 1997)
"Carvedilol is a multiple-action cardiovascular agent that is both a beta-adrenoceptor antagonist and a vasodilator and has recently been made available for the treatment of mild-to-moderate hypertension."	2.67	Myocardial protection with carvedilol. ( Bril, A; Feuerstein, GZ; Hamburger, SA; Ruffolo, RR; Smith, EF, 1992)
"Carvedilol is a non-selective β-blocker with α₁-adrenergic receptor antagonism properties."	2.48	A critical review of the use of carvedilol in ischemic heart disease. ( Abrencillo, R; Chen-Scarabelli, C; Di Rezze, J; Faggian, G; Gardin, T; Gidwani, UK; Murad, Y; Qureshi, W; Saravolatz, L; Scarabelli, TM; Shieh, WS, 2012)
"Carvedilol is a beta(1)- and beta(2)-adrenergic receptor antagonist with additional vasodilatory alpha(1)-blocking properties."	2.45	Role of carvedilol controlled-release in cardiovascular disease. ( Fonarow, GC, 2009)
" In addition, some patients are treated with agents whose long-term use has not been shown to be effective."	2.43	Beta-blockers for the post-myocardial infarction patient: current clinical evidence and practical considerations. ( Fonarow, GC, 2006)
" This study assesses the impact of β-blocker type and dosing on survival in patients with DM after MI."	1.91	Impact of Diabetes Mellitus on Benefit of β-Blocker Therapy After Myocardial Infarction. ( Abbott, JD; Bello, D; Blandon, C; Goldberger, JJ; Subačius, H; Zaatari, G, 2023)
" Beta-blocker dosage groups were >0% to12."	1.62	Comparison of Metoprolol Versus Carvedilol After Acute Myocardial Infarction. ( Fintel, DJ; Germano, JJ; Goldberger, JJ; Shani, J; Subacius, H; Zaatari, G, 2021)
"Hallucinations are rarely reported and as far as we know the only reported couple of cases were on metoprolol and propranolol, none has been reported with Carvedilol."	1.51	The Man Who Saw Things on Carvedilol. ( Aikoye, SA; Jafferany, M; Osuagwu, V; Plath, DL, 2019)
"Crude incidence of cardiac death and/or recurrent myocardial infarction (cardiac death/MI) tended to be higher in the β group (7."	1.39	β-Blocker therapy and cardiovascular outcomes in patients who have undergone percutaneous coronary intervention after ST-elevation myocardial infarction. ( Bao, B; Fujiwara, H; Furukawa, Y; Hayano, M; Iwabuchi, M; Kadota, K; Kato, Y; Kimura, T; Kita, T; Mitsudo, K; Morimoto, T; Nakagawa, Y; Natsuaki, M; Nobuyoshi, M; Ozasa, N; Shiomi, H; Shizuta, S; Tada, T; Tazaki, J, 2013)
" The number and type of antihypertensive drugs have increased dramatically from 28 diuretics in 1972 to over 125 agents today, including fixed dose combination dosage forms."	1.36	The foundation role of beta blockers across the cardiovascular disease spectrum: a year 2009 update. ( Black, HR; Greenberg, BH; Weber, MA, 2010)
"Carvedilol treatment restored the IS reduction by postconditioning, possibly via other mechanism(s) of the ERK and Akt pathways."	1.35	Attenuation of cardioprotective effect by postconditioning in coronary stenosed rat heart and its restoration by carvedilol. ( Maruyama, Y; Oikawa, M; Watanabe, K; Yaoita, H, 2008)
"Carvedilol is a combined alpha(1)- and beta-adrenoceptor antagonist."	1.33	Carvedilol blockade of alpha1- and beta-adrenoceptor induced inotropic responses in rats with congestive heart failure. ( Bøkenes, J; Osnes, JB; Qvigstad, E; Schiander, I; Sejersted, OM; Sjaastad, I; Skomedal, T; Solberg, L, 2005)
"Treatment with carvedilol 1) reduced the pro-inflammatory cytokines and fibrogenic cytokine TGF-beta1 levels in myocardium and was associated with the amelioration of the elevated left ventricular diastolic pressure."	1.33	Effects of carvedilol on cardiac cytokines expression and remodeling in rat with acute myocardial infarction. ( Cheng, X; Ge, H; Guo, H; Li, B; Liao, YH; Wang, M, 2006)
"Carvedilol is an alpha-and beta-blocking agent with antioxidant properties."	1.33	In vivo chronic carvedilol treatment in rats attenuates ex vivo regional infarction of the heart. ( Hegna, S; Johansen, OE; Mjøs, OD; Munch-Ellingsen, J; Starkopf, J; Ytrehus, K, 2006)
"Carvedilol is a beta-adrenoceptor blocker with a vasodilatory action that is more effective for the treatment of congestive heart failure than other beta-blockers."	1.32	Beta-adrenoceptor blocker carvedilol provides cardioprotection via an adenosine-dependent mechanism in ischemic canine hearts. ( Asakura, M; Asano, Y; Asanuma, H; Hori, M; Kim, J; Kitakaze, M; Kitamura, S; Liao, Y; Minamino, T; Mori, H; Node, K; Ogai, A; Ogita, H; Sanada, S; Shinozaki, Y; Shintani, Y; Takashima, S; Tomoike, H, 2004)
"SB 211475 was administered either as 0."	1.30	SB 211475, a metabolite of carvedilol, reduces infarct size after myocardial ischemic and reperfusion injury in rabbits. ( Brunvand, H; Feuerstein, GZ; Liu, G; Ma, XL; Ruffolo, RR; Yue, TL, 1998)
"Carvedilol-treated animals exhibited a 78% reduction in infarct size compared to vehicle controls, such that the percentage of the left ventricle infarcted was reduced significantly from 16."	1.28	Carvedilol (Kredex) reduces infarct size in a canine model of acute myocardial infarction. ( Barone, FC; Feuerstein, GZ; Hamburger, SA; Ruffolo, RR, 1991)

Research

Studies (163)

Authors

Clinical Trials (12)

Trial Overview

Trial Outcomes

Change From Baseline in BNP Levels

Change From Baseline in Deceleration Time

Change From Baseline in Early to Late Atrial Ratio (E:A Ratio)

Change From Baseline in End Diastolic Dimension (EDD)

Change From Baseline in End Systolic Dimension (ESD)

Change From Baseline in Intraventricular Septal Thickness (IVST)

Change From Baseline in Left Ventricular Ejection Fraction (LVEF)

Change From Baseline in Left Ventricular End Diastolic Volume (LVEDV)

Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)

Change From Baseline in Left Ventricular End Systolic Volume (LVESV)

Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI) Characterized by 2-D Echocardiography

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (0.61)	18.7374
1990's	19 (11.66)	18.2507
2000's	88 (53.99)	29.6817
2010's	44 (26.99)	24.3611
2020's	11 (6.75)	2.80

Authors	Studies
Asdaq, SMB	1
Alamri, AS	1
Alsanie, WF	1
Alhomrani, M	1
Ortiz, VD	3
Teixeira, RB	1
Türck, P	3
Corssac, GB	1
Belló-Klein, A	3
de Castro, AL	2
Araujo, ASDR	2
Zaatari, G	2
Bello, D	1
Blandon, C	1
Abbott, JD	1
Subačius, H	2
Goldberger, JJ	2
Amano, M	1
Izumi, C	1
Watanabe, H	1
Ozasa, N	2
Morimoto, T	2
Bingyuan, B	1
Suwa, S	1
Miyake, M	1
Tamura, T	1
Nakagawa, Y	2
Kadota, K	2
Inuzuka, Y	1
Minamimoto, Y	1
Furukawa, Y	2
Kaji, S	1
Suzuki, T	1
Akao, M	1
Inada, T	1
Kimura, T	3
Zafeiropoulos, S	1
Stavrakis, S	1
Adachi, M	1
Watanabe, M	1
Kurata, Y	1
Inoue, Y	1
Notsu, T	1
Yamamoto, K	2
Horie, H	1
Tanno, S	1
Morita, M	1
Miake, J	1
Hamada, T	1
Kuwabara, M	1
Nakasone, N	1
Ninomiya, H	1
Tsuneto, M	1
Shirayoshi, Y	1
Yoshida, A	1
Nishimura, M	1
Hisatome, I	1
Teixeira, R	2
Fintel, DJ	1
Germano, JJ	1
Shani, J	1
Zhang, JG	1
Dai, SP	1
Liu, H	1
Xu, ZS	1
Baraka, SA	1
Tolba, MF	1
Elsherbini, DA	1
El-Naga, RN	1
Awad, AS	1
El-Demerdash, E	1
Wang, X	1
Sun, Q	1
Hu, W	1
Aonuma, T	2
Moukette, B	1
Kawaguchi, S	1
Barupala, NP	1
Sepúlveda, MN	1
Corr, C	1
Tang, Y	7
Liangpunsakul, S	1
Payne, RM	1
Willis, MS	1
Kim, IM	2
Li, J	1
Chen, Z	4
Gao, X	1
Zhang, H	1
Xiong, W	1
Ju, J	3
Xu, H	1
Bayoumi, AS	1
Park, KM	1
Wang, Y	3
Teoh, JP	1
Su, H	1
Weintraub, NL	1
Ferreira, JP	1
Girerd, N	1
Gregson, J	1
Latar, I	1
Sharma, A	1
Pfeffer, MA	1
McMurray, JJV	1
Abdul-Rahim, AH	1
Pitt, B	1
Dickstein, K	1
Rossignol, P	1
Zannad, F	1
Domagoj, M	1
Branka, JZ	1
Jelena, M	1
Davor, M	1
Duska, G	1
Zullo, AR	1
Hersey, M	1
Lee, Y	1
Sharmin, S	1
Bosco, E	1
Daiello, LA	1
Shah, NR	1
Mor, V	1
Boscardin, WJ	1
Berard-Collins, CM	1
Dore, DD	1
Steinman, MA	1
Franken, PR	1
Woltersdorf, R	1
Nemoto, S	1
Kasahara, Y	1
Izawa, KP	1
Watanabe, S	1
Yoshizawa, K	1
Takeichi, N	1
Kamiya, K	1
Suzuki, N	1
Omiya, K	1
Matsunaga, A	1
Akashi, YJ	1
Hu, Y	3
Chen, X	2
Li, X	4
Li, Z	1
Diao, H	1
Liu, L	1
Zhang, J	1
Wen, L	1
Liu, X	1
Pan, Z	1
Xu, C	2
Hai, X	1
Zhang, Y	2
Lima-Seolin, BG	1
Lacerda, D	1
Fraga, SF	1
Hickmann, A	1
Gatelli Fernandes, TR	1
Luz de Castro, A	1
da Rosa Araujo, AS	1
Aikoye, SA	1
Jafferany, M	1
Osuagwu, V	1
Plath, DL	1
Grandinetti, V	1
Carlos, FP	1
Antonio, EL	1
de Oliveira, HA	1
Dos Santos, LFN	1
Yoshizaki, A	1
Mansano, BSDM	1
Silva, FA	1
Porte, LA	1
Albuquerque-Pontes, GM	1
de Carvalho, PTC	1
Manchini, MT	1
Leal-Junior, EC	1
Tucci, PJF	1
Serra, AJ	1
Yeh, CH	1
Chen, TP	1
Wang, YC	1
Lin, YM	1
Fang, SW	1
Fonarow, G	1
Dantas, EM	1
Pimentel, EB	1
Andreão, RV	1
Cichoni, BS	1
Gonçalves, CP	1
Zaniqueli, Ddos A	1
Baldo, MP	1
Rodrigues, SL	1
Mill, JG	1
Liu, CC	1
Huang, Y	1
Zhang, JH	1
Xu, Y	1
Wu, CH	1
Zhu, JN	1
Chen, R	1
Fu, YH	1
Lin, QX	1
Huang, S	1
Guo, LL	1
Zhang, MZ	1
Deng, CY	1
Zou, X	1
Zhong, SL	1
Yang, M	1
Zhuang, J	1
Yu, XY	1
Shan, ZX	1
Hou, L	1
Du, N	1
Guan, X	1
Liu, Z	1
Zhang, T	1
Qin, W	1
Shen, N	1
Bilal, MU	1
Lu, Y	1
Shan, H	1
Arnold, SV	1
Spertus, JA	1
Lipska, KJ	1
Lanfear, DE	1
Tang, F	1
Grodzinsky, A	1
McGuire, DK	1
Gore, MO	1
Goyal, A	1
Maddox, TM	1
Kosiborod, M	1
Akgüllü, Ç	1
Eryılmaz, U	1
Güngör, H	1
Huyut, A	1
Zencir, C	1
Hekim, T	1
Vakaliuk, IP	1
Tymochko, NB	1
Ahmed, Z	1
Bajwa, A	1
Bhardwaj, B	1
Laster, SB	1
Magalski, A	1
Seo, GW	1
Kim, DK	1
Kim, KH	2
Seol, SH	1
Jin, HY	1
Yang, TH	1
Ahn, Y	2
Jeong, MH	2
Song, PS	1
Kim, DI	2
Oh, PC	1
Kang, WC	1
Moon, J	1
Park, YM	1
Kim, S	1
Kim, MG	1
Lee, K	1
Ahn, T	1
Shin, EK	1
Zhang, R	1
Kang, X	1
Wang, F	1
Yu, P	1
Shen, J	1
Fu, L	1
Cao, F	2
Huang, C	2
Jiang, H	4
Bao, M	1
Carter, NJ	1
Keating, GM	1
Gogorishvili, I	1
Archvadze, A	1
Kipiani, V	1
Kipshidze, N	1
Zhao, JL	1
Yang, YJ	4
Pei, WD	1
Sun, YH	1
Zhai, M	1
Liu, YX	1
Gao, RL	4
Oikawa, M	2
Yaoita, H	2
Watanabe, K	2
Maruyama, Y	2
Sun, T	1
Shen, LH	1
Chen, H	1
Li, HW	1
Guo, CY	1
Li, ZZ	1
Tang, CS	1
Fonarow, GC	3
Wen, H	2
Lu, Z	2
He, B	2
Hu, X	2
Chen, J	3
Zhao, D	1
Tsuda, E	1
Minami, N	1
Kobayashi, J	1
Fukaya, T	1
Nozaki, H	1
Noritake, K	1
Echigo, S	1
Geng, ZH	1
Liu, CY	1
Peng, YH	1
Li, LG	1
Zhao, XH	1
Cui, B	1
Yu, SY	1
Yoshikawa, E	1
Marui, A	1
Tsukashita, M	1
Nishina, T	1
Wang, J	1
Muranaka, H	1
Ikeda, T	1
Komeda, M	1
Zhang, JL	1
Lu, JK	1
Chen, D	1
Cai, Q	1
Li, TX	1
Wu, LS	1
Wu, XS	1
Tang, Q	1
Afanas'ev, SA	1
Kondrat'eva, DS	1
Putrova, OD	1
Perchatkin, VA	1
Repin, AN	1
Popov, SV	1
Remme, WJ	3
Cimmino, G	1
Ibanez, B	1
Giannarelli, C	1
Prat-González, S	1
Hutter, R	1
Garcia, M	1
Sanz, J	1
Fuster, V	1
Badimon, JJ	1
Nahar, N	1
Akhter, N	1
Black, HR	1
Greenberg, BH	2
Weber, MA	1
Yu, J	1
Zhao, J	2
Liu, W	1
Ge, Z	1
Du, Y	1
Self, T	1
Rogers, ML	1
Mancell, J	1
Soberman, JE	1
Bakaev, RG	1
Strutynskiĭ, AV	1
Kallaeva, AN	1
Glazunov, AB	1
Voronina, MA	1
Pekhtereva, DA	1
Moshkova, NK	1
Chudnovskaia, EA	1
Kochetkov, BM	1
Gafurova, RM	1
Abdullaev, AA	1
Kadieva, IA	1
Islamova, UA	1
Mutalipov, KhM	1
Konishi, M	1
Haraguchi, G	1
Yoshikawa, S	1
Kimura, S	1
Inagaki, H	1
Isobe, M	1
Seino, Y	1
Lee, R	1
DiNicolantonio, JJ	2
Hackam, DG	1
Chen, B	1
Li, Y	4
Jiang, S	1
Xie, YP	1
Guo, A	1
Kutschke, W	1
Zimmerman, K	1
Weiss, RM	1
Miller, FJ	1
Anderson, ME	1
Song, LS	1
Lin, M	1
Zhu, CX	1
Liu, Y	1
Gao, JL	1
Xu, B	1
Fu, YC	1
Lan, YF	1
Zhang, JC	1
Hassan, F	1
Meduru, S	1
Taguchi, K	1
Kuppusamy, ML	1
Mostafa, M	1
Kuppusamy, P	1
Khan, M	1
Bao, B	1
Iwabuchi, M	1
Shizuta, S	1
Shiomi, H	1
Tada, T	1
Tazaki, J	1
Kato, Y	1
Hayano, M	1
Natsuaki, M	1
Fujiwara, H	1
Mitsudo, K	1
Nobuyoshi, M	1
Kita, T	1
Chen-Scarabelli, C	1
Saravolatz, L	2
Murad, Y	1
Shieh, WS	1
Qureshi, W	1
Di Rezze, J	1
Abrencillo, R	1
Gardin, T	1
Gidwani, UK	1
Faggian, G	1
Scarabelli, TM	1
Lavie, CJ	1
Fares, H	1
Menezes, AR	1
O'Keefe, JH	1
Otterstad, JE	1
Ford, I	2
Schultheiss, HP	1
Tschöpe, C	1
Isnard, R	1
Jonsson, G	3
Fossum, E	1
Kjeldsen, SE	3
Høieggen, A	1
Os, I	3
Eide, I	1
Westheim, A	2
Fleming, T	1
Borer, J	1
Armstrong, PW	1
Pfeffer, M	1
Tang, YD	2
Ruan, YM	3
Zhang, P	3
Zhou, YW	2
Wang, PH	2
Chen, JL	3
Chen, ZJ	3
Giallauria, F	1
Paragliola, T	1
Del Forno, D	1
Baiano, A	1
de Cristofaro, A	1
Rossi, M	1
Vigorito, C	1
Lu, SQ	1
Sun, RC	1
Schwarz, ER	1
Kersting, PH	1
Reffelmann, T	1
Meven, DA	1
Al-Dashti, R	1
Skobel, EC	1
Klosterhalfen, B	1
Hanrath, P	2
Sackner-Bernstein, JD	1
Doughty, RN	2
Whalley, GA	1
Walsh, HA	1
Gamble, GD	1
López-Sendón, J	2
Sharpe, N	2
Yang, Y	5
Ruan, Y	3
Gao, R	4
Cha, KS	1
Kim, MH	1
Kim, JW	1
Kim, HJ	1
Kim, DS	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Comparison of Carvedilol and Atenolol on Anti-anginal and Metabolic Effects in Patients With Stable Angina Pectoris[NCT02547597]	Phase 4	99 participants (Actual)	Interventional	2011-04-30	Completed
A Multicenter,Randomized, Double Blind, Double Dummy, Parallel Group Study to Compare Effects of Coreg CR and Coreg IR on Left Ventricular End Systolic Volume Index in Subjects With Stable Chronic Heart Failure[NCT00323037]	Phase 3	318 participants (Actual)	Interventional	2006-03-31	Completed
aMsa and amiOdarone Study in cArdiaC Arrest[NCT04997980]		500 participants (Anticipated)	Observational	2015-01-01	Recruiting
[NCT00257959]	Phase 4	400 participants	Interventional	2001-01-31	Completed
A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events: A Pilot Study[NCT01945268]	Phase 4	107 participants (Actual)	Interventional	2015-04-30	Completed
A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events[NCT02762851]	Phase 4	5,000 participants (Anticipated)	Interventional	2016-06-30	Recruiting
A Single Centre, Retrospective Cohort Study on Post Analysis on the Link Between the Clinical Heart Rate and Outcomes During PCI[NCT02351674]		15,000 participants (Anticipated)	Observational	2015-01-31	Not yet recruiting
Heart Rate Lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease[NCT01365286]	Phase 4	40 participants (Actual)	Interventional	2009-05-31	Completed
Photoplethysmography (PPG) to Predict Ejection Fraction and Other Echographic Data in the General Population[NCT04843371]		200 participants (Actual)	Observational	2021-08-20	Completed
Congestive Heart Failure Atrial Arrhythmia Monitoring and Pacing (CHAMP)[NCT00156728]	Phase 4	172 participants	Interventional	2003-10-31	Completed
Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure[NCT00832442]		18,240 participants (Anticipated)	Observational	2008-08-31	Enrolling by invitation
The PACE-MI Registry Study - Outcomes of Beta-blocker Therapy After Myocardial Infarction (OBTAIN)[NCT00430612]		7,057 participants (Actual)	Observational [Patient Registry]	2009-05-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	percentage of change (Mean)
Carvedilol Immediate Release	-0.88
Carvedilol Controlled Release	-0.86

Intervention	percentage of change (Mean)
Carvedilol Immediate Release	24.00
Carvedilol Controlled Release	53.37

Intervention	percentage of change (Mean)
Carvedilol Immediate Release	-0.20
Carvedilol Controlled Release	-0.45

Intervention	percentage of change (Mean)
Carvedilol Immediate Release	-0.33
Carvedilol Controlled Release	-0.36

Intervention	percentage of change (Mean)
Carvedilol Immediate Release	-0.76
Carvedilol Controlled Release	-0.83

Intervention	percentage of change (Mean)
Carvedilol Immediate Release	.08
Carvedilol Controlled Release	.05

Intervention	percentage of change (Mean)
Carvedilol Immediate Release	.08
Carvedilol Controlled Release	.08

Intervention	percentage of change (Mean)
Carvedilol Immediate Release	-36.61
Carvedilol Controlled Release	-42.22

Intervention	percentage of change (Mean)
Carvedilol Immediate Release	-18.29
Carvedilol Controlled Release	-20.57

Intervention	percentage of change (Mean)
Carvedilol Immediate Release	-36.61
Carvedilol Controlled Release	-43.00

Maintenance Visit 3 minus Baseline. Maintenance Visit 3 occurred 24 weeks after entry into the maintenance period. The maintenance period started after completion of a titration period of variable duration. (NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period

Change From Baseline in Left Ventricular Mass (LVM)

Change From Baseline in Posterior Wall Thickness (PWT)

Safety and Tolerability of Coreg CR

Intervention	mL/m^2 (Mean)
Coreg Immediate Release	-18.36
Coreg Controlled Release	-20.81

Intervention	percentage of change (Mean)
Carvedilol Immediate Release	9.5
Carvedilol Controlled Release	-9.29

Intervention	percentage of change (Mean)
Carvedilol Immediate Release	.07
Carvedilol Controlled Release	.05

SAEs experienced (NCT00323037)
Timeframe: 24 weeks after entry into the maintenance phase (after unblinding)

Article	Year
Meta-Analysis Comparing Metoprolol and Carvedilol on Mortality Benefits in Patients With Acute Myocardial Infarction. The American journal of cardiology, 2017, Nov-01, Volume: 120, Issue:9 Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Carbazoles; C	2017
Spontaneous coronary artery dissection: the management dilemma continues. BMJ case reports, 2015, Aug-13, Volume: 2015 Topics: Adenosine; Adult; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Carbazol	2015
Controlled-release carvedilol. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2008, Volume: 8, Issue:4 Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedi	2008
Role of carvedilol controlled-release in cardiovascular disease. Expert review of cardiovascular therapy, 2009, Volume: 7, Issue:5 Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carvedilol; Delayed-Action Prepara	2009
Carvedilol therapy after cocaine-induced myocardial infarction in patients with asthma. The American journal of the medical sciences, 2011, Volume: 342, Issue:1 Topics: Adrenergic beta-1 Receptor Antagonists; Asthma; Carbazoles; Carvedilol; Clinical Trials as Topic; Co	2011
Carvedilol: a third-generation β-blocker should be a first-choice β-blocker. Expert review of cardiovascular therapy, 2012, Volume: 10, Issue:1 Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Atenolol; Biomarkers; Carbazoles; Car	2012
A critical review of the use of carvedilol in ischemic heart disease. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Dec-01, Volume: 12, Issue:6 Topics: Adrenergic beta-Antagonists; Angina, Stable; Animals; Anti-Arrhythmia Agents; Antioxidants; Arrhythm	2012
Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol). The American journal of cardiology, 2013, Mar-01, Volume: 111, Issue:5 Topics: Adrenergic beta-1 Receptor Antagonists; Atenolol; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; E	2013
[Congestive heart failure and acute myocardial infarction: latest trials with beta-blocking agents]. Annales de cardiologie et d'angeiologie, 2002, Volume: 51, Issue:1 Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol;	2002
New evidence from the CAPRICORN Trial: the role of carvedilol in high-risk, post-myocardial infarction patients. Reviews in cardiovascular medicine, 2003, Volume: 4 Suppl 3 Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Therapy, Combination; Humans; Myocardial I	2003
Cardiac remodeling in coronary artery disease. The American journal of cardiology, 2004, May-06, Volume: 93, Issue:9A Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Echocardiography; Heart Failure; Humans; Myocar	2004
Use of beta-blockers in older adults with chronic heart failure. The American journal of the medical sciences, 2004, Volume: 328, Issue:2 Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiovascu	2004
A review of carvedilol arrhythmia data in clinical trials. Journal of cardiovascular pharmacology and therapeutics, 2005, Volume: 10 Suppl 1 Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Ca	2005
Beta-blockers for the post-myocardial infarction patient: current clinical evidence and practical considerations. Reviews in cardiovascular medicine, 2006,Winter, Volume: 7, Issue:1 Topics: Adrenergic beta-Antagonists; Algorithms; Atenolol; Carbazoles; Carvedilol; Humans; Myocardial Infarc	2006
Effect of beta blockers, particularly carvedilol, on reducing the risk of events after acute myocardial infarction. The American journal of cardiology, 2006, Oct-15, Volume: 98, Issue:8 Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Humans; Myocardia	2006
Carvedilol: use in chronic heart failure. Expert review of cardiovascular therapy, 2007, Volume: 5, Issue:1 Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Diabe	2007
Resting heart rate in cardiovascular disease. Journal of the American College of Cardiology, 2007, Aug-28, Volume: 50, Issue:9 Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca	2007
Resting heart rate in cardiovascular disease. Journal of the American College of Cardiology, 2007, Aug-28, Volume: 50, Issue:9 Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca	2007
Resting heart rate in cardiovascular disease. Journal of the American College of Cardiology, 2007, Aug-28, Volume: 50, Issue:9 Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca	2007
Resting heart rate in cardiovascular disease. Journal of the American College of Cardiology, 2007, Aug-28, Volume: 50, Issue:9 Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Carbazoles; Ca	2007
Switching to once-daily evidence-based [beta]-blockers in patients with systolic heart failure or left ventricular dysfunction after myocardial infarction. Critical care nurse, 2007, Volume: 27, Issue:6 Topics: Adrenergic beta-Antagonists; Algorithms; Carbazoles; Carvedilol; Delayed-Action Preparations; Eviden	2007
Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. European heart journal, 1995, Volume: 16 Suppl F Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Antioxidants; Arteriosclerosis; Carb	1995
[Value of beta-blocker therapy in treatment of coronary heart disease and sudden cardiac death with special reference to carvedilol]. Zeitschrift fur Kardiologie, 1996, Volume: 85 Suppl 7 Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cause of Death; Coronary Disease; Death, Sudden	1996
Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. European journal of heart failure, 2001, Volume: 3, Issue:3 Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Cachexia; Carbazoles; Carboxylic Acids; Carvedilol	2001
Pathophysiology and triggers of acute myocardial infarction: clinical implications. The Clinical investigator, 1992, Volume: 70 Suppl 1 Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Arousal; Carbazoles; Carvedilol; Circadian Rhy	1992
Pharmacological and clinical aspects of drug therapy in coronary heart disease: clinical aspects of therapy with beta-adrenoceptor antagonists. Zeitschrift fur Kardiologie, 1990, Volume: 79 Suppl 3 Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Coronary Disease; Hemodynamics; Humans	1990

Article	Year
Effects of Long-Term Carvedilol Therapy in Patients With ST-Segment Elevation Myocardial Infarction and Mildly Reduced Left Ventricular Ejection Fraction. The American journal of cardiology, 2023, 07-15, Volume: 199 Topics: Carvedilol; Heart Failure; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; ST Ele	2023
Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. Journal of the American College of Cardiology, 2018, 02-20, Volume: 71, Issue:7 Topics: Aged; Atrial Fibrillation; Carvedilol; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocard	2018
Impact of Carvedilol versus β1-selective β blockers (bisoprolol, metoprolol, and nebivolol) in patients with acute myocardial infarction undergoing percutaneous coronary intervention. The American journal of cardiology, 2015, Nov-15, Volume: 116, Issue:10 Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Carbazo	2015
Anti-Anginal and Metabolic Effects of Carvedilol and Atenolol in Patients with Stable Angina Pectoris: A Prospective, Randomized, Parallel, Open-Label Study. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2016, Volume: 16, Issue:3 Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angina, Stable; Atenolol; Carbazoles; Cardiotonic Agen	2016
[Efficacy of ramipril, carvedilol, and trimetazidine MR in improvement of quality of life of patients after myocardial infarction]. Kardiologiia, 2010, Volume: 50, Issue:12 Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol;	2010
Additive effects of β-blockers on renin-angiotensin system inhibitors for patients after acute myocardial infarction treated with primary coronary revascularization. Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:8 Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Ang	2011
The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blo European journal of heart failure, 2002, Volume: 4, Issue:4 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Double-Blind Me	2002
Lower plasma noradrenaline and blood viscosity on carvedilol vs atenolol in men with recent myocardial infarction. Blood pressure, 2002, Volume: 11, Issue:6 Topics: Adrenergic alpha-Antagonists; Atenolol; Blood Glucose; Blood Pressure; Blood Viscosity; Carbazoles;	2002
Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation, 2004, Jan-20, Volume: 109, Issue:2 Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Female; Heart Rate; Humans; Kin	2004
Comparison between a sustained administration of carvedilol versus atenolol to reduce restenosis after coronary stenting. American heart journal, 2004, Volume: 147, Issue:2 Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Atenolol; C	2004
Landmark study: the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN). The American journal of cardiology, 2004, May-06, Volume: 93, Issue:9A Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Female; Humans; Male; Myoc	2004
Carvedilol versus metoprolol in patients undergoing direct percutaneous coronary interventions for myocardial infarction: effects on QT dynamicity. Pacing and clinical electrophysiology : PACE, 2005, Volume: 28 Suppl 1 Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Carbazole	2005
Carvedilol versus metoprolol in the acute phase of myocardial infarction:. Pacing and clinical electrophysiology : PACE, 2005, Volume: 28 Suppl 1 Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Carbazoles; Carvedilol; Female; Heart R	2005
Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. Journal of the American College of Cardiology, 2005, Feb-15, Volume: 45, Issue:4 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Carbazoles; Carve	2005
A comparison of the two beta-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction. a single-centre, randomized study of 232 patients. Cardiology, 2005, Volume: 103, Issue:3 Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Carbazoles; Carvedilol; Female; Gated Blood-Pool Imagin	2005
Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET. American heart journal, 2005, Volume: 149, Issue:2 Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Double-Blind Method; Fe	2005
[Carvedilol in combined therapy of patients with Q myocardial infarction]. Terapevticheskii arkhiv, 2005, Volume: 77, Issue:8 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Atenolol; Carbazoles; Carvedilol; Drug	2005
Does carvedilol have antiarrhythmic properties? Nature clinical practice. Cardiovascular medicine, 2005, Volume: 2, Issue:7 Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Follow-Up Studies; Humans	2005
Comparison of carvedilol and metoprolol in patients with acute myocardial infarction undergoing primary coronary intervention--the PASSAT Study. Clinical research in cardiology : official journal of the German Cardiac Society, 2006, Volume: 95, Issue:1 Topics: Administration, Oral; Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Carbazoles; Carve	2006
After myocardial infarction carvedilol improves insulin resistance compared to metoprolol. Clinical research in cardiology : official journal of the German Cardiac Society, 2006, Volume: 95, Issue:2 Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; C-Peptide; Carbazoles; Carve	2006
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation, 2006, Jul-11, Volume: 114, Issue:2 Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol	2006
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation, 2006, Jul-11, Volume: 114, Issue:2 Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol	2006
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation, 2006, Jul-11, Volume: 114, Issue:2 Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol	2006
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation, 2006, Jul-11, Volume: 114, Issue:2 Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol	2006
[Estimation of effectiveness of the prevention of sudden cardiac death in patients with myocardial infarction]. Georgian medical news, 2006, Issue:135 Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Female; Humans; Male; M	2006
Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. The American journal of cardiology, 2006, Oct-02, Volume: 98, Issue:7A Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Area Under Curve; Canada; C	2006
The antioxidative effects of long-term treatment are more pronounced for carvedilol than for atenolol in post-myocardial infarction patients. Journal of cardiovascular pharmacology, 2007, Volume: 49, Issue:1 Topics: Antioxidants; Atenolol; Carbazoles; Carvedilol; Female; Humans; Long-Term Care; Male; Middle Aged; M	2007
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. Journal of the American College of Cardiology, 2007, Mar-06, Volume: 49, Issue:9 Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl	2007
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. Journal of the American College of Cardiology, 2007, Mar-06, Volume: 49, Issue:9 Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl	2007
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. Journal of the American College of Cardiology, 2007, Mar-06, Volume: 49, Issue:9 Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl	2007
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. Journal of the American College of Cardiology, 2007, Mar-06, Volume: 49, Issue:9 Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl	2007
[Effect of low doses of metoprolol, bisoprolol and carvedilol on mortality in patients with left ventricular dysfunction after acute myocardial infarction]. Wiadomosci lekarskie (Warsaw, Poland : 1960), 2006, Volume: 59, Issue:9-10 Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Aged; Angioplasty, Balloon, Coronary; Bisoprolol;	2006
The early anti-oxidant effect of carvedilol predicts the clinical course in congestive heart failure patients. Journal of cardiovascular medicine (Hagerstown, Md.), 2007, Volume: 8, Issue:6 Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Hu	2007
Randomized active-controlled study comparing effects of treatment with carvedilol versus metoprolol in patients with left ventricular dysfunction after acute myocardial infarction. American heart journal, 2007, Volume: 154, Issue:1 Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cause of Death; Disease-Free Survival; Female;	2007
Carvedilol increases copper-zinc superoxide dismutase activity in patients with acute myocardial infarction. Basic & clinical pharmacology & toxicology, 2007, Volume: 101, Issue:2 Topics: Adrenergic Antagonists; Carbazoles; Carvedilol; Drug Therapy, Combination; Erythrocytes; Female; Fre	2007
[The effects of beta-adrenoblocker therapy on the physical working capacity of patients with chronic heart failure of various origin]. Klinicheskaia meditsina, 2007, Volume: 85, Issue:5 Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles;	2007
Effects of carvedilol early after myocardial infarction: analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN). American heart journal, 2007, Volume: 154, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Comorbidity; Double-Blind Method; Female; Hu	2007
Effects of carvedilol on the metabolic, hemodynamic, and electrocardiographic responses to increased plasma epinephrine in normal subjects. Journal of cardiovascular pharmacology, 1994, Volume: 24, Issue:6 Topics: Adrenergic beta-Antagonists; Adult; Blood Glucose; Carbazoles; Carvedilol; Drug Interactions; Electr	1994
Vasodilating beta-blockers in heart failure. European heart journal, 1995, Volume: 16 Suppl F Topics: Administration, Oral; Adrenergic beta-Antagonists; Angina Pectoris; Carbazoles; Carvedilol; Dose-Res	1995
The association between cardiac events and myocardial ischaemia following thrombolysis in acute myocardial infarction and the impact of carvedilol. European heart journal, 1996, Volume: 17 Suppl F Topics: Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Confidence Intervals; Coronary Angiography;	1996
Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. Circulation, 1997, Jul-01, Volume: 96, Issue:1 Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Dizziness; Echocard	1997
Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction. American heart journal, 1999, Volume: 137, Issue:4 Pt 1 Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Double-Blind Method; Echocardiogra	1999
Design and methodology of the CAPRICORN trial - a randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction. European journal of heart failure, 2000, Volume: 2, Issue:3 Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Humans; Incidence; Myocard	2000
CAPRICORN: a story of alpha allocation and beta-blockers in left ventricular dysfunction post-MI. International journal of cardiology, 2001, Volume: 78, Issue:2 Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Approval; Humans; Myocardial Infarction; P	2001
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001, May-05, Volume: 357, Issue:9266 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra	2001
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001, May-05, Volume: 357, Issue:9266 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra	2001
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001, May-05, Volume: 357, Issue:9266 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra	2001
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001, May-05, Volume: 357, Issue:9266 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra	2001
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001, May-05, Volume: 357, Issue:9266 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra	2001
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001, May-05, Volume: 357, Issue:9266 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra	2001
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001, May-05, Volume: 357, Issue:9266 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra	2001
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001, May-05, Volume: 357, Issue:9266 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra	2001
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001, May-05, Volume: 357, Issue:9266 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra	2001
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001, May-05, Volume: 357, Issue:9266 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra	2001
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001, May-05, Volume: 357, Issue:9266 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra	2001
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001, May-05, Volume: 357, Issue:9266 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra	2001
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001, May-05, Volume: 357, Issue:9266 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra	2001
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001, May-05, Volume: 357, Issue:9266 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra	2001
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001, May-05, Volume: 357, Issue:9266 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra	2001
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001, May-05, Volume: 357, Issue:9266 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra	2001
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001, May-05, Volume: 357, Issue:9266 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra	2001
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001, May-05, Volume: 357, Issue:9266 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra	2001
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001, May-05, Volume: 357, Issue:9266 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra	2001
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001, May-05, Volume: 357, Issue:9266 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra	2001
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001, May-05, Volume: 357, Issue:9266 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra	2001
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001, May-05, Volume: 357, Issue:9266 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra	2001
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001, May-05, Volume: 357, Issue:9266 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra	2001
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001, May-05, Volume: 357, Issue:9266 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra	2001
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England), 2001, May-05, Volume: 357, Issue:9266 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Administra	2001
Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. European journal of heart failure, 2001, Volume: 3, Issue:3 Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Cachexia; Carbazoles; Carboxylic Acids; Carvedilol	2001
[Antioxidant and antiarrhythmic activity of carvedilol in patients with ischemic heart disease. Comparison with anaprilin]. Terapevticheskii arkhiv, 2001, Volume: 73, Issue:10 Topics: Adrenergic beta-Antagonists; Angina Pectoris; Anti-Arrhythmia Agents; Antioxidants; Arrhythmias, Car	2001
Myocardial protection with carvedilol. Journal of cardiovascular pharmacology, 1992, Volume: 19 Suppl 1 Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Coronary Disease; Dogs; Heart; Injecti	1992
[The acute hemodynamic effects of the new vasodilating beta blocker carvedilol in comparison with combined administration of nifedipine and propranolol in patients with coronary heart disease]. Zeitschrift fur Kardiologie, 1989, Volume: 78, Issue:11 Topics: Carbazoles; Carvedilol; Coronary Circulation; Coronary Disease; Drug Therapy, Combination; Female; H	1989

Article	Year
Cardioprotective Potential of Garlic Oil and Its Active Constituent, Diallyl Disulphide, in Presence of Carvedilol during Chronic Isoprenaline Injection-Mediated Myocardial Necrosis in Rats. Molecules (Basel, Switzerland), 2021, Aug-25, Volume: 26, Issue:17 Topics: Allyl Compounds; Animals; Antioxidants; Cardiotonic Agents; Carvedilol; Catalase; Disease Models, An	2021
Influence of carvedilol and thyroid hormones on inflammatory proteins and cardioprotective factor HIF-1α in the infarcted heart. Canadian journal of physiology and pharmacology, 2023, Feb-01, Volume: 101, Issue:2 Topics: Animals; Carvedilol; Male; Myeloid Differentiation Factor 88; Myocardial Infarction; NLR Family, Pyr	2023
Impact of Diabetes Mellitus on Benefit of β-Blocker Therapy After Myocardial Infarction. The American journal of cardiology, 2023, 07-01, Volume: 198 Topics: Adrenergic beta-Antagonists; Carvedilol; Diabetes Mellitus; Humans; Metoprolol; Myocardial Infarctio	2023
Long-Term Carvedilol Therapy in Patients With ST-Segment Elevation Myocardial Infarction and Preserved Systolic Function: A Long-Standing Conundrum. The American journal of cardiology, 2023, 08-01, Volume: 200 Topics: Carvedilol; Humans; Myocardial Infarction; ST Elevation Myocardial Infarction; Treatment Outcome	2023
β-Adrenergic Blocker, Carvedilol, Abolishes Ameliorating Actions of Adipose-Derived Stem Cell Sheets on Cardiac Dysfunction and Remodeling After Myocardial Infarction. Circulation journal : official journal of the Japanese Circulation Society, 2019, 10-25, Volume: 83, Issue:11 Topics: Adrenergic beta-Antagonists; Animals; Carvedilol; Cell Hypoxia; Cells, Cultured; Disease Models, Ani	2019
Effects of Carvedilol and Thyroid Hormones Co-administration on Apoptotic and Survival Proteins in the Heart After Acute Myocardial Infarction. Journal of cardiovascular pharmacology, 2020, Volume: 76, Issue:6 Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Apoptosis; Apoptosis Regulatory Proteins; Carvedil	2020
Comparison of Metoprolol Versus Carvedilol After Acute Myocardial Infarction. The American journal of cardiology, 2021, 05-15, Volume: 147 Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Carvedilol; Female; Hospitalization; Humans; Kaplan-M	2021
Comparison of carvedilol versus metoprolol in patients with acute myocardial infarction: A protocol for systematic review and meta-analysis. Medicine, 2021, May-21, Volume: 100, Issue:20 Topics: Arrhythmias, Cardiac; Carvedilol; Death, Sudden, Cardiac; Humans; Meta-Analysis as Topic; Metoprolol	2021
Rosuvastatin and low-dose carvedilol combination protects against isoprenaline-induced myocardial infarction in rats: Role of PI3K/Akt/Nrf2/HO-1 signalling. Clinical and experimental pharmacology & physiology, 2021, Volume: 48, Issue:10 Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Anticholesteremic Agents; Apoptosis;	2021
Carvedilol Protects Against the H2O2-induced Cell Damages in Rat Myoblasts by Regulating the Circ_NFIX/miR-125b-5p/TLR4 Signal Axis. Journal of cardiovascular pharmacology, 2021, 10-01, Volume: 78, Issue:4 Topics: Animals; Antioxidants; Apoptosis; Carvedilol; Cell Cycle Checkpoints; Cell Line; Cell Proliferation;	2021
Cardiomyocyte microRNA-150 confers cardiac protection and directly represses proapoptotic small proline-rich protein 1A. JCI insight, 2021, 09-22, Volume: 6, Issue:18 Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; Carvedilol; Cornified Envelope Proline-Rich Protein	2021
A carvedilol-responsive microRNA, miR-125b-5p protects the heart from acute myocardial infarction by repressing pro-apoptotic bak1 and klf13 in cardiomyocytes. Journal of molecular and cellular cardiology, 2018, Volume: 114 Topics: Animals; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Cardiotonic Agents; Carvedilol; Cell	2018
Effects of carvedilol therapy in patients with heart failure with preserved ejection fraction - Results from the Croatian heart failure (CRO-HF) registry. Medicina clinica, 2019, 01-18, Volume: 152, Issue:2 Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carvedilol; Comorbidity; Croatia; Diabetes Mel	2019
Outcomes of "diabetes-friendly" vs "diabetes-unfriendly" β-blockers in older nursing home residents with diabetes after acute myocardial infarction. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:12 Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Blood Glucose; Carvedilol; Diabetes Mellitus, Type 2	2018
Risk of renal dysfunction in an elderly patient with chronic heart failure. Medizinische Monatsschrift fur Pharmazeuten, 2016, Volume: 39, Issue:10 Topics: Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carvedilol; Diclofenac; Digoxin; Drug Interactio	2016
Effect of carvedilol on heart rate response to cardiopulmonary exercise up to the anaerobic threshold in patients with subacute myocardial infarction. Heart and vessels, 2019, Volume: 34, Issue:6 Topics: Adrenergic beta-Antagonists; Aged; Anaerobic Threshold; Carvedilol; Cross-Sectional Studies; Exercis	2019
MicroRNA‑1 downregulation induced by carvedilol protects cardiomyocytes against apoptosis by targeting heat shock protein 60. Molecular medicine reports, 2019, Volume: 19, Issue:5 Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Carvedilol; Cell Survival; Cells, Cultured; Chaperon	2019
Carvedilol and thyroid hormones co-administration mitigates oxidative stress and improves cardiac function after acute myocardial infarction. European journal of pharmacology, 2019, Jul-05, Volume: 854 Topics: Animals; Antioxidants; Carvedilol; Drug Synergism; Electrocardiography; Glutathione Disulfide; Heart	2019
The Man Who Saw Things on Carvedilol. The Tokai journal of experimental and clinical medicine, 2019, Jul-20, Volume: 44, Issue:2 Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Carvedilol; Hallucinations; Hu	2019
Photobiomodulation therapy combined with carvedilol attenuates post-infarction heart failure by suppressing excessive inflammation and oxidative stress in rats. Scientific reports, 2019, 07-01, Volume: 9, Issue:1 Topics: Animals; Carvedilol; Catalase; Disease Models, Animal; Echocardiography; Female; Heart Failure; Hemo	2019
Carvedilol treatment after myocardial infarct decreases cardiomyocytic apoptosis in the peri-infarct zone during cardioplegia-induced cardiac arrest. Shock (Augusta, Ga.), 2013, Volume: 39, Issue:4 Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; Biomarkers; Carbazoles; Carvedilol; Dose-Response R	2013
Update on pharmacological advances. The Journal of invasive cardiology, 2004, Volume: 16 Suppl E Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Disea	2004
Carvedilol recovers normal blood pressure variability in rats with myocardial infarction. Autonomic neuroscience : basic & clinical, 2013, Volume: 177, Issue:2 Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressure; Carba	2013
Effect of carvedilol on cardiac dysfunction 4 days after myocardial infarction in rats: role of toll-like receptor 4 and β-arrestin 2. European review for medical and pharmacological sciences, 2013, Volume: 17, Issue:15 Topics: Animals; Arrestins; beta-Arrestin 2; beta-Arrestins; Carbazoles; Cardiotonic Agents; Carvedilol; Hea	2013
Smad3 inactivation and MiR-29b upregulation mediate the effect of carvedilol on attenuating the acute myocardium infarction-induced myocardial fibrosis in rat. PloS one, 2013, Volume: 8, Issue:9 Topics: Animals; Carbazoles; Cardiotonic Agents; Carvedilol; Down-Regulation; Fibroblasts; Fibrosis; Heart;	2013
β-Blocker carvedilol protects cardiomyocytes against oxidative stress-induced apoptosis by up-regulating miR-133 expression. Journal of molecular and cellular cardiology, 2014, Volume: 75 Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; Carbazoles; Cardiotonic Agents; Carvedilol; Caspase	2014
Type of β-blocker use among patients with versus without diabetes after myocardial infarction. American heart journal, 2014, Volume: 168, Issue:3 Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Contraindications; Diabetic Angiopathies;	2014
A clinical study about contrast nephropathy: risk factors and the role of beta blockers. Anatolian journal of cardiology, 2015, Volume: 15, Issue:3 Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Contrast Media; Cross-Sectional Studies; Female	2015
[Characteristics of medical use of Korvazan® for restorative treatment of patients with myocardial infarction, counting the risk factors]. Likars'ka sprava, 2013, Issue:8 Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Dose-Response Relationship, Drug;	2013
Effects of carvedilol on ventricular remodeling and the expression of β3-adrenergic receptor in a diabetic rat model subjected myocardial infarction. International journal of cardiology, 2016, Nov-01, Volume: 222 Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Diabetes Mellitus, Experimental; Diabe	2016
The influence of carvedilol on atrial connexin 40 after myocardial infarction. Acta cardiologica, 2008, Volume: 63, Issue:3 Topics: Adrenergic beta-Antagonists; Animals; Blotting, Western; Carbazoles; Carvedilol; Connexins; Disease	2008
Treatment of patients with cardiogenic shock in the setting of acute myocardial infarction. Case reports. Georgian medical news, 2008, Issue:162 Topics: Aged; Angioplasty, Balloon; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carbazoles; Carvedilol	2008
Carvedilol reduces myocardial no-reflow by decreasing endothelin-1 via activation of the ATP-sensitive K+ channel. Perfusion, 2008, Volume: 23, Issue:2 Topics: Animals; Antihypertensive Agents; Carbazoles; Carvedilol; Disease Models, Animal; Endothelin-1; Glyb	2008
Attenuation of cardioprotective effect by postconditioning in coronary stenosed rat heart and its restoration by carvedilol. Circulation journal : official journal of the Japanese Circulation Society, 2008, Volume: 72, Issue:12 Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Coronary Stenosis; Disease Models, Ani	2008
[Effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction]. Zhonghua xin xue guan bing za zhi, 2008, Volume: 36, Issue:1 Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Collagen; Disease Models, Animal; Fibr	2008
[Effect of carvedilol on parameters of myocardial perfusion in patients with left ventricular remodeling after myocardial infarction]. Kardiologiia, 2009, Volume: 49, Issue:2 Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Coronary Circulation; Dose-Response Rela	2009
Carvedilol ameliorates the decreases in connexin 43 and ventricular fibrillation threshold in rats with myocardial infarction. The Tohoku journal of experimental medicine, 2009, Volume: 218, Issue:2 Topics: Animals; Blotting, Western; Carbazoles; Carvedilol; Connexin 43; Disease Models, Animal; Fluorescent	2009
Acute myocardial infarction after Kawasaki disease in an infant: treatment with coronary artery bypass grafting. Pediatrics international : official journal of the Japan Pediatric Society, 2009, Volume: 51, Issue:3 Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Coronary Aneurysm; Coronary Angiography; Corona	2009
[Effect of carvedilol and perindopril on Ca(2+) pump activity and Ca(2+)-release channel density in myocardial sarcoplasmic reticulum in rats with chronic heart failure following myocardial infarction]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2009, Volume: 29, Issue:7 Topics: Animals; Calcium; Carbazoles; Carvedilol; Drug Therapy, Combination; Heart Failure; Male; Myocardial	2009
Carvedilol may alleviate late cardiac remodelling following surgical ventricular restoration. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2010, Volume: 37, Issue:2 Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Cardiac Catheterization; Carvedilol; Drug Evaluati	2010
Myocardial autophagy variation during acute myocardial infarction in rats: the effects of carvedilol. Chinese medical journal, 2009, Oct-05, Volume: 122, Issue:19 Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1;	2009
Carvedilol ameliorates sympathetic nerve sprouting and electrical remodeling after myocardial infarction in rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2010, Volume: 64, Issue:7 Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Autonomic Pathways; C	2010
[Effect of nonselective beta-adrenoblocker carvedilol on extrasystolic and postextrasystolic contractility in the rat myocardium after experimental infarction]. Eksperimental'naia i klinicheskaia farmakologiia, 2010, Volume: 73, Issue:2 Topics: Adrenergic beta-Antagonists; Age Factors; Animals; Calcium; Carbazoles; Carvedilol; Electric Stimula	2010
Which beta-blocker is most effective in heart failure? Cardiovascular drugs and therapy, 2010, Volume: 24, Issue:4 Topics: Adrenergic beta-Antagonists; Animals; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Clinical Tria	2010
Carvedilol administration in acute myocardial infarction results in stronger inhibition of early markers of left ventricular remodeling than metoprolol. International journal of cardiology, 2011, Dec-15, Volume: 153, Issue:3 Topics: Animals; Biomarkers; Carbazoles; Carvedilol; Down-Regulation; Metoprolol; Myocardial Infarction; Pro	2011
Effect of carvedilol on adrenaline-induced changes in serum electrolytes in rat. Bangladesh Medical Research Council bulletin, 2009, Volume: 35, Issue:3 Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Disease Models, Animal; Drug Interacti	2009
The foundation role of beta blockers across the cardiovascular disease spectrum: a year 2009 update. The American journal of medicine, 2010, Volume: 123, Issue:11 Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Benzopyrans; Carbazoles; Cardiovascular Diseas	2010
Combined effects of irbesartan and carvedilol on expression of tissue factor and tissue factor pathway inhibitor in rats after myocardial infarction. Heart and vessels, 2011, Volume: 26, Issue:6 Topics: Adrenergic Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood	2011
[Effects of long-term therapy with angiotensin-converting enzyme inhibitor and carvedilol on the heart remodeling process after non-Q-wave myocardial infarction]. Klinicheskaia meditsina, 2011, Volume: 89, Issue:1 Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Drug	2011
Beta-blocker therapy for patients with acute myocardial infarction. -Implications in the post-successful PCI Era in Japan-. Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:8 Topics: Adrenergic beta-1 Receptor Antagonists; Angioplasty, Balloon, Coronary; Angiotensin Receptor Antagon	2011
Ask the doctor. I had a heart attack three years ago at age 78. My doctor started me on lisinopril, carvedilol, and aspirin. My total cholesterol is 190, and my LDL is 128. Should I be taking a statin? Harvard heart letter : from Harvard Medical School, 2011, Volume: 21, Issue:12 Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Carbazoles; Carvedil	2011
β-Adrenergic receptor antagonists ameliorate myocyte T-tubule remodeling following myocardial infarction. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2012, Volume: 26, Issue:6 Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Caveolin 3; Male; Membrane Proteins; M	2012
[Effect of carvedilol on T-type calcium current in myocytes of non-infarcted area of the rabbit healed myocardial infarction]. Yao xue xue bao = Acta pharmaceutica Sinica, 2012, Volume: 47, Issue:2 Topics: Adrenergic beta-Antagonists; Animals; Calcium Channels, T-Type; Carbazoles; Carvedilol; Female; Male	2012
Carvedilol enhances mesenchymal stem cell therapy for myocardial infarction via inhibition of caspase-3 expression. The Journal of pharmacology and experimental therapeutics, 2012, Volume: 343, Issue:1 Topics: Animals; Carbazoles; Carvedilol; Caspase 3; Caspase Inhibitors; Cell Survival; Cells, Cultured; Comb	2012
β-Blocker therapy and cardiovascular outcomes in patients who have undergone percutaneous coronary intervention after ST-elevation myocardial infarction. Cardiovascular intervention and therapeutics, 2013, Volume: 28, Issue:2 Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Combined Modality Ther	2013
[Beta blockers in post-infarction state]. Herz, 2002, Volume: 27 Suppl 1 Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Therapy, Combination; Heart Failure; Human	2002
Food and Drug Administration: Cardiovascular and Renal Drugs Advisory Committee, 98th meeting, January 6th-7th, 2003. Circulation, 2003, Jan-21, Volume: 107, Issue:2 Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Atenolol; Ca	2003
Comparative effects of carvedilol and losartan alone and in combination for preventing left ventricular remodeling after acute myocardial infarction in rats. Circulation journal : official journal of the Japanese Circulation Society, 2003, Volume: 67, Issue:2 Topics: Animals; Carbazoles; Carvedilol; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; He	2003
[Cardiac rehabilitation in a HIV-patient treated with protease inhibitors]. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2003, Volume: 60, Issue:1 Topics: Adult; Aspirin; Carbazoles; Carvedilol; Cholesterol; Coronary Angiography; Diet Therapy; Drug Therap	2003
[Comparative effects of carvedilol and metoprolol in preventing from left ventricular remodeling after acute myocardial infarction in rats]. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2001, Volume: 23, Issue:5 Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Female; Metoprolol; Myocardial Infarct	2001
Cardioprotection by Carvedilol: antiapoptosis is independent of beta-adrenoceptor blockage in the rat heart. Journal of cardiovascular pharmacology and therapeutics, 2003, Volume: 8, Issue:3 Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; Carbazoles; Carvedilol; Female; Heart; Hemodynamics	2003
Comparison of metoprolol with low, middle and high doses of carvedilol in prevention of postinfarction left ventricular remodeling in rats. Japanese heart journal, 2003, Volume: 44, Issue:6 Topics: Animals; Carbazoles; Cardiac Volume; Carvedilol; Dose-Response Relationship, Drug; Female; Heart Rat	2003
The European Society of Cardiology working group on heart failure: Heart Failure Update 2003. Heart failure monitor, 2003, Volume: 4, Issue:2 Topics: Carbazoles; Cardiac Pacing, Artificial; Carvedilol; Eplerenone; Europe; Heart Failure; Humans; Metop	2003
Beta-adrenoceptor blocker carvedilol provides cardioprotection via an adenosine-dependent mechanism in ischemic canine hearts. Circulation, 2004, Jun-08, Volume: 109, Issue:22 Topics: 5'-Nucleotidase; Adenosine; Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Cells, Cul	2004
[Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction]. Kardiologiia, 2004, Volume: 44, Issue:10 Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti	2004
The beta-adrenergic blocker carvedilol restores L-type calcium current in a myocardial infarction model of rabbit. Chinese medical journal, 2005, Mar-05, Volume: 118, Issue:5 Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Calcium Channels, L-Type; Carbazoles; Carve	2005
[Effects of carvedilol on the expression of IL-1beta and collagen precipitation in myocardium in post-myocardial infarction rats ]. Zhonghua yi xue za zhi, 2005, Feb-16, Volume: 85, Issue:6 Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Collagen; Interleukin-1; Male; Myocard	2005
Carvedilol blockade of alpha1- and beta-adrenoceptor induced inotropic responses in rats with congestive heart failure. European journal of pharmacology, 2005, May-23, Volume: 516, Issue:1 Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Carbaz	2005
[Experimental study of effect of carvedilol on myocardial collagen network remodeling after acute myocardial infarction in rats]. Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue, 2005, Volume: 17, Issue:9 Topics: Animals; Biphenyl Compounds; Carbazoles; Carvedilol; Collagen; Disease Models, Animal; Hemodynamics;	2005
Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats. Chest, 2005, Volume: 128, Issue:3 Topics: Adrenergic beta-Antagonists; Animals; Calcium-Binding Proteins; Calcium-Transporting ATPases; Carbaz	2005
[Comparative effects of carvedilol, losartan and their combination in preventing left ventricular remodeling after acute myocardial infarction in rats]. Zhonghua nei ke za zhi, 2001, Volume: 40, Issue:12 Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Carbazoles; Carvedilo	2001
Effects of carvedilol on cardiac cytokines expression and remodeling in rat with acute myocardial infarction. International journal of cardiology, 2006, Aug-10, Volume: 111, Issue:2 Topics: Animals; Carbazoles; Carvedilol; Cytokines; Disease Models, Animal; Heart; Interleukin-10; Interleuk	2006
Clinical trials update from the American College of Cardiology: Darbepoetin alfa, ASTEROID, UNIVERSE, paediatric carvedilol, UNLOAD and ICELAND. European journal of heart failure, 2006, Volume: 8, Issue:3 Topics: Carbazoles; Carvedilol; Child; Cholesterol, LDL; Clinical Trials as Topic; Darbepoetin alfa; Diureti	2006
[Beneficial effects of carvedilol on cardiomyocyte apoptosis and bcl-2/bax expression after acute myocardial infarction an experiment with rats]. Zhonghua yi xue za zhi, 2006, Apr-04, Volume: 86, Issue:13 Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Carb	2006
Attenuated cardioprotection by ischemic preconditioning in coronary stenosed heart and its restoration by carvedilol. Cardiovascular research, 2006, Aug-01, Volume: 71, Issue:3 Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Coronary Stenosis; Drug Evaluation, Pr	2006
Management of cardiovascular risk in patients receiving calcineurin inhibitors--a case report. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2006, Volume: 21 Suppl 3 Topics: Acenocoumarol; Amiodarone; Angioplasty; Calcineurin Inhibitors; Carbazoles; Carvedilol; Cyclosporine	2006
Carvedilol preserves endothelial junctions and reduces myocardial no-reflow after acute myocardial infarction and reperfusion. International journal of cardiology, 2007, Feb-14, Volume: 115, Issue:3 Topics: Adrenergic alpha-Antagonists; Animals; Blood Flow Velocity; Blotting, Western; Carbazoles; Carvedilo	2007
In vivo chronic carvedilol treatment in rats attenuates ex vivo regional infarction of the heart. Scandinavian cardiovascular journal : SCJ, 2006, Volume: 40, Issue:4 Topics: Adrenergic alpha-Antagonists; Animals; Carbazoles; Carvedilol; Diastole; Ischemic Preconditioning, M	2006
Beta-adrenoreceptor antagonists attenuate brain injury after transient focal ischemia in rats. Anesthesia and analgesia, 2006, Volume: 103, Issue:3 Topics: Adrenergic beta-Antagonists; Anesthesia; Anesthetics, Inhalation; Animals; Brain; Carbazoles; Carved	2006
Effect of combination therapy with simvastatin and carvedilol in patients with left ventricular dysfunction complicated with acute myocardial infarction who underwent percutaneous coronary intervention. Circulation journal : official journal of the Japanese Circulation Society, 2006, Volume: 70, Issue:10 Topics: Aged; Angioplasty, Balloon, Coronary; Carbazoles; Carvedilol; Death; Disease-Free Survival; Drug Eva	2006
[Role of the drug interaction between carvedilol and dobutamine in inducing of severe hypotension in a case with acute coronary syndrome]. Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2007, Volume: 7, Issue:2 Topics: Aged; Carbazoles; Cardiotonic Agents; Carvedilol; Diagnosis, Differential; Dobutamine; Drug Interact	2007
Ask the doctor. Does a low ejection fraction doom me to inactivity? Harvard heart letter : from Harvard Medical School, 2007, Volume: 17, Issue:9 Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiac Output, Low; Cardiotonic Agents; Carvedilol;	2007
Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity. Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1993, Volume: 11, Issue:4 Topics: Adrenergic beta-Antagonists; Animals; Antioxidants; Carbazoles; Carvedilol; Dogs; Free Radical Scave	1993
Cardioprotective potential of carvedilol. Cardiology, 1993, Volume: 82 Suppl 3 Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Diltiazem; Dogs; Free Radical Scavenge	1993
Carvedilol improves function and reduces infarct size in the feline myocardium by protecting against lethal reperfusion injury. European journal of pharmacology, 1996, Oct-24, Volume: 314, Issue:1-2 Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Cats; Coronary Vessels; Hemodynamics;	1996
Carvedilol following AMI. The Journal of family practice, 1997, Volume: 45, Issue:4 Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carvedilol; Double-Blind Method; H	1997
Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model. European journal of pharmacology, 1998, Jun-26, Volume: 351, Issue:3 Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antioxidants; Blood Pressure; Ca	1998
SB 211475, a metabolite of carvedilol, reduces infarct size after myocardial ischemic and reperfusion injury in rabbits. European journal of pharmacology, 1998, Sep-04, Volume: 356, Issue:2-3 Topics: Adrenergic alpha-Antagonists; Animals; Antioxidants; Carbazoles; Carvedilol; Dose-Response Relations	1998
Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction. Journal of the American College of Cardiology, 2000, Volume: 36, Issue:1 Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Carbazoles; Carvedil	2000
[Comparative effects of carvediol in large, middle, and small dose in preventing left ventricular remodeling after acute myocardial infarction in rats]. Zhonghua yi xue za zhi, 2001, Aug-10, Volume: 81, Issue:15 Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Fema	2001
Long-term effects of carvedilol on left ventricular function, remodeling, and expression of cardiac cytokines after large myocardial infarction in the rat. Journal of cardiovascular pharmacology, 2002, Volume: 39, Issue:1 Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Cytokines; Fibrosis; Gas Chromatograph	2002
[Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial]. Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology, 2001, Volume: 2, Issue:11 Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Humans; Multicenter Studies as Topic; Myocardia	2001
[CAPRICORN and COPERINUS studies]. Archives des maladies du coeur et des vaisseaux, 2002, Volume: 95 Spec 4, Issue:5 Spec 4 Topics: Adrenergic beta-Agonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiac Output, Low;	2002
Comparative effects of cilazapril, carvedilol and their combination in preventing from left ventricular remodelling after acute myocardial infarction in rats. Journal of the renin-angiotensin-aldosterone system : JRAAS, 2002, Volume: 3, Issue:1 Topics: Acute Disease; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Carba	2002
Effect of beta blockers on new congestive heart failure in older persons with healed myocardial infarcts. The American journal of cardiology, 2002, Jul-01, Volume: 90, Issue:1 Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Heart Failure; Humans; Myocardial Infarct	2002
Cardioprotective effects of the vasodilator/beta-adrenoceptor blocker, carvedilol, in two models of myocardial infarction in the rat. Pharmacology, 1992, Volume: 44, Issue:6 Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Disease Models, Animal; Dose-Response	1992
Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranolol. Cardiovascular research, 1992, Volume: 26, Issue:5 Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilo	1992
Carvedilol (Kredex) reduces infarct size in a canine model of acute myocardial infarction. Pharmacology, 1991, Volume: 43, Issue:3 Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Coronary Vessels; Dimethylformamide; D	1991

carvedilol and Myocardial Infarction